

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use ProQuad safely and effectively. See full prescribing information for ProQuad.

ProQuad®

Measles, Mumps, Rubella and Varicella Virus Vaccine Live
Suspension for intramuscular or subcutaneous injection

Initial U.S. Approval: 2005

INDICATIONS AND USAGE

ProQuad is a vaccine indicated for active immunization for the prevention of measles, mumps, rubella, and varicella in children 12 months through 12 years of age. (1)

DOSAGE AND ADMINISTRATION

For intramuscular or subcutaneous injection only. (2.1, 2.3)

A single dose is approximately 0.5 mL.

- The first dose is administered at 12 to 15 months of age. (2.1)
- The second dose is administered at 4 to 6 years of age. (2.1)

DOSAGE FORMS AND STRENGTHS

Suspension for injection (approximately 0.5 mL dose) supplied as a lyophilized vaccine to be reconstituted using accompanying sterile diluent. (2.2, 3)

CONTRAINDICATIONS

- Hypersensitivity to any component of the vaccine. (4.1)
- Immunosuppression. (4.2)
- Moderate or severe febrile illness. (4.3)
- Active untreated tuberculosis. (4.4)
- Pregnancy. (4.5, 8.1)

WARNINGS AND PRECAUTIONS

- Administration of ProQuad (dose 1) to children 12 to 23 months old who have not been previously vaccinated against measles, mumps, rubella, or varicella, nor had a history of the wild-type infections, is associated with higher rates of fever and febrile seizures at 5 to 12 days after vaccination when compared to children vaccinated with M-M-R® II and VARIVAX® administered separately. Exercise caution when administering ProQuad to persons with an individual or family history of febrile seizures. (5.1, 6.1, 6.3)
- Use caution when administering ProQuad to children with anaphylaxis or immediate hypersensitivity following egg ingestion. (5.2)
- Use caution when administering ProQuad to children with thrombocytopenia. (5.3)
- Evaluate individuals for immune competence prior to administration of ProQuad if there is a family history of congenital or hereditary immunodeficiency. (5.4)

- Avoid close contact with high-risk individuals susceptible to varicella because of possible transmission of varicella vaccine virus. (5.6)
- Immune Globulins (IG) and other blood products should not be given concurrently with ProQuad. (5.7, 7.1)
- Avoid using salicylates for 6 weeks after vaccination with ProQuad. (5.8, 7.2, 17)

ADVERSE REACTIONS

- The most frequent vaccine-related adverse events reported in ≥5% of subjects vaccinated with ProQuad were:
 - injection-site reactions (pain/tenderness/soreness, erythema, and swelling)
 - fever
 - irritability. (6.1)
- Systemic vaccine-related adverse events that were reported at a significantly greater rate in recipients of ProQuad than in recipients of the component vaccines administered concomitantly were:
 - fever
 - measles-like rash. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Merck Sharp & Dohme LLC at 1-877-888-4231 or VAERS at 1-800-822-7967 or www.vaers.hhs.gov.

DRUG INTERACTIONS

- Administration of immune globulins and other blood products concurrently with ProQuad vaccine may interfere with the expected immune response. (7.1)
- ProQuad vaccination may result in a temporary depression of purified protein derivative (PPD) tuberculin skin sensitivity. (7.4)
- ProQuad may be administered concomitantly with *Haemophilus influenzae* type b conjugate vaccine and/or hepatitis B vaccine at separate injection sites. (7.5)
- ProQuad may be administered concomitantly with pneumococcal 7-valent conjugate vaccine and/or hepatitis A vaccine (inactivated) at separate injection sites. (7.5)

USE IN SPECIFIC POPULATIONS

Pregnancy: Do not administer ProQuad to females who are pregnant. Pregnancy should be avoided for 3 months following vaccination with ProQuad. (4.5, 8.1, 17)

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.

Revised: 11/2024

FULL PRESCRIBING INFORMATION: CONTENTS*

1 INDICATIONS AND USAGE

2 DOSAGE AND ADMINISTRATION

- 2.1 Dose and Schedule
- 2.2 Preparation for Administration
- 2.3 Administration

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

- 4.1 Hypersensitivity
- 4.2 Immunosuppression
- 4.3 Moderate or Severe Febrile Illness
- 4.4 Active Untreated Tuberculosis
- 4.5 Pregnancy

5 WARNINGS AND PRECAUTIONS

- 5.1 Fever and Febrile Seizures
- 5.2 Hypersensitivity to Eggs
- 5.3 Thrombocytopenia
- 5.4 Family History of Immunodeficiency
- 5.5 Use in HIV-Infected Individuals
- 5.6 Risk of Vaccine Virus Transmission
- 5.7 Immune Globulins and Transfusions
- 5.8 Salicylate Therapy

6 ADVERSE REACTIONS

- 6.1 Clinical Trials Experience
- 6.2 Post-Marketing Experience

6.3 Post-Marketing Observational Safety Surveillance Study

7 DRUG INTERACTIONS

- 7.1 Immune Globulins and Transfusions
- 7.2 Salicylates
- 7.3 Corticosteroids and Immunosuppressive Drugs
- 7.4 Drug/Laboratory Test Interactions
- 7.5 Use with Other Vaccines

8 USE IN SPECIFIC POPULATIONS

- 8.1 Pregnancy
- 8.2 Lactation
- 8.4 Pediatric Use
- 8.5 Geriatric Use

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

- 12.1 Mechanism of Action
- 12.6 Persistence of Antibody Responses after Vaccination

13 NONCLINICAL TOXICOLOGY

- 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

14 CLINICAL STUDIES

15 REFERENCES

16 HOW SUPPLIED/STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION

*Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

ProQuad is a vaccine indicated for active immunization for the prevention of measles, mumps, rubella, and varicella in children 12 months through 12 years of age.

2 DOSAGE AND ADMINISTRATION

For Intramuscular or Subcutaneous administration only

2.1 Dose and Schedule

A single dose of ProQuad is approximately 0.5 mL.

The first dose is administered at 12 to 15 months of age but may be given anytime through 12 years of age.

The second dose is administered at 4 to 6 years of age.

At least 1 month should elapse between a dose of a measles-containing vaccine and a dose of ProQuad. At least 3 months should elapse between a dose of varicella-containing vaccine and ProQuad.

2.2 Preparation for Administration

The sterile diluent for ProQuad is provided in either a vial or prefilled syringe.

Sterile Diluent Vial

Use a sterile syringe free of preservatives, antiseptics, and detergents for each injection and/or reconstitution of the vaccine because these substances may inactivate the live virus vaccine. To reconstitute, use the sterile diluent vial supplied with ProQuad. The sterile diluent does not contain preservatives or other antiviral substances which might inactivate the vaccine viruses.

To reconstitute the vaccine, withdraw the entire volume of the supplied sterile diluent from the vial and slowly inject into the lyophilized vaccine vial. Gently agitate to dissolve completely. Discard if the lyophilized vaccine cannot be dissolved.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Visually inspect the vaccine before and after reconstitution prior to administration. Before reconstitution, the lyophilized vaccine is a white to pale yellow compact crystalline plug. ProQuad, when reconstituted, is a clear pale yellow to light pink liquid. Do not use the reconstituted vaccine if particulates are present or if it appears discolored.

Withdraw and administer the entire volume of the reconstituted vaccine.

Administer ProQuad immediately after reconstitution. If not used immediately, the reconstituted vaccine may be stored at room temperature, protected from light, for up to 30 minutes. Discard reconstituted vaccine if it is not used within 30 minutes.

Sterile Diluent Prefilled Syringe

To reconstitute, use the sterile diluent prefilled syringe supplied with the vaccine since it does not contain preservatives or other antiviral substances which might inactivate the vaccine viruses.

Attach a needle to the prefilled syringe.

Reconstitute the vaccine by slowly injecting the entire volume of sterile diluent contained in the prefilled syringe into the lyophilized vaccine vial. Gently agitate to dissolve completely. Discard if the lyophilized vaccine cannot be dissolved.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Visually inspect the vaccine before and after reconstitution prior to administration. Before reconstitution, the lyophilized vaccine is a white to pale yellow compact crystalline plug. ProQuad, when reconstituted, is a clear pale yellow to light pink liquid. Do not use the reconstituted vaccine if particulates are present or if it appears discolored.

Withdraw and administer the entire volume of the reconstituted vaccine.

Administer ProQuad immediately after reconstitution. If not used immediately, the reconstituted vaccine may be stored at room temperature, protected from light, for up to 30 minutes. Discard reconstituted vaccine if it is not used within 30 minutes.

2.3 Administration

Inject the vaccine intramuscularly or subcutaneously.

3 DOSAGE FORMS AND STRENGTHS

ProQuad is a suspension for injection supplied as a single dose vial of lyophilized vaccine to be reconstituted using the accompanying sterile diluent [see *Dosage and Administration (2.2)* and *How Supplied/Storage and Handling (16)*]. A single dose after reconstitution is approximately 0.5 mL.

4 CONTRAINDICATIONS

4.1 Hypersensitivity

Do not administer ProQuad to individuals with a history of hypersensitivity to any component of the vaccine (including gelatin) {1} or to a previous dose of M-M-R II (Measles, Mumps, Rubella, Live), ProQuad or VARIVAX (Varicella Virus Vaccine Live) vaccine, or any other measles, mumps, and rubella or varicella-containing vaccine. Do not administer ProQuad to individuals with a history of anaphylaxis to neomycin [see *Description (11)*].

4.2 Immunosuppression

Do not administer ProQuad vaccine to individuals who are immunodeficient or immunosuppressed due to disease or medical therapy. Measles inclusion body encephalitis {2} (MIBE), pneumonitis {3} and death as a direct consequence of disseminated measles vaccine virus infection have been reported in immunocompromised individuals inadvertently vaccinated with measles-containing vaccine. In this population, disseminated mumps and rubella vaccine virus infection have also been reported. Disseminated varicella disease and extensive vaccine-associated rash have been reported in individuals who are immunosuppressed or immunodeficient who were inadvertently vaccinated with a varicella-containing vaccine {4}.

4.3 Moderate or Severe Febrile Illness

Do not administer ProQuad to individuals with an active febrile illness with fever >101.3°F (>38.5°C).

4.4 Active Untreated Tuberculosis

Do not administer ProQuad vaccine to individuals with active untreated tuberculosis (TB).

4.5 Pregnancy

Do not administer ProQuad to individuals who are pregnant or planning on becoming pregnant in the next 3 months [see *Use in Specific Populations (8.1)* and *Patient Counseling Information (17)*].

5 WARNINGS AND PRECAUTIONS

5.1 Fever and Febrile Seizures

Administration of ProQuad (dose 1) to children 12 to 23 months old who have not been previously vaccinated against measles, mumps, rubella, or varicella, nor had a history of the wild-type infections, is associated with higher rates of fever and febrile seizures at 5 to 12 days after vaccination when compared to children vaccinated with a first dose of M-M-R II and VARIVAX administered concomitantly [see *Adverse Reactions (6.3)*]. Exercise caution when administering ProQuad to persons with an individual or family history of febrile seizures.

5.2 Hypersensitivity to Eggs

Individuals with a history of anaphylactic, anaphylactoid, or other immediate reactions (e.g., hives, swelling of the mouth and throat, difficulty breathing, hypotension, or shock) subsequent to egg ingestion may be at an enhanced risk of immediate-type hypersensitivity reactions after receiving ProQuad vaccine. The potential risks and known benefits should be evaluated before considering vaccination in these individuals [see *Contraindications (4.1)*] {5}.

5.3 Thrombocytopenia

Transient thrombocytopenia has been reported within 4-6 weeks following vaccination with measles, mumps and rubella vaccine. Carefully evaluate the potential risk and benefit of vaccination in children with thrombocytopenia or in those who experienced thrombocytopenia after vaccination with a previous dose of a measles, mumps, and rubella-containing vaccine [see *Adverse Reactions (6.2)*] {6-8}.

5.4 Family History of Immunodeficiency

Vaccination should be deferred in individuals with a family history of congenital or hereditary immunodeficiency until the individual's immune status has been evaluated and the individual has been found to be immunocompetent.

5.5 Use in HIV-Infected Individuals

The Advisory Committee on Immunization Practices (ACIP) has recommendations on the use of varicella vaccine in HIV-infected individuals.

5.6 Risk of Vaccine Virus Transmission

Post-licensing experience suggests that transmission of varicella vaccine virus (Oka/Merck) resulting in varicella infection including disseminated disease may occur between vaccine recipients (who develop or do not develop a varicella-like rash) and contacts susceptible to varicella including healthy as well as high-risk individuals.

High-risk individuals susceptible to varicella include:

- Immunocompromised individuals;
- Pregnant women without documented positive history of varicella (chickenpox) or laboratory evidence of prior infection;
- Newborn infants of mothers without documented positive history of varicella or laboratory evidence of prior infection and all newborn infants born at <28 weeks gestation regardless of maternal varicella immunity.

Vaccine recipients should attempt to avoid, to the extent possible, close association with high-risk individuals susceptible to varicella for up to 6 weeks following vaccination. In circumstances where contact with high-risk individuals susceptible to varicella is unavoidable, the potential risk of transmission of the varicella vaccine virus should be weighed against the risk of acquiring and transmitting wild-type varicella virus.

Excretion of small amounts of the live, attenuated rubella virus from the nose or throat has occurred in the majority of susceptible individuals 7 to 28 days after vaccination. There is no confirmed evidence to indicate that such virus is transmitted to susceptible persons who are in contact with the vaccinated individuals. Consequently, transmission through close personal contact, while accepted as a theoretical possibility, is not regarded as a significant risk. However, transmission of the rubella vaccine virus to infants via breast milk has been documented [see *Use in Specific Populations* (8.2)].

There are no reports of transmission of the more attenuated Enders' Edmonston strain of measles virus or the Jeryl Lynn™ strain of mumps virus from vaccine recipients to susceptible contacts.

5.7 Immune Globulins and Transfusions

Immune Globulins (IG) and other blood products should not be given concurrently with ProQuad [see *Drug Interactions* (7.1)]. These products may contain antibodies that interfere with vaccine virus replication and decrease the expected immune response.

The ACIP has specific recommendations for intervals between administration of antibody containing products and live virus vaccines.

5.8 Salicylate Therapy

Avoid the use of salicylates (aspirin) or salicylate-containing products in children and adolescents 12 months through 12 years of age, for six weeks following vaccination with ProQuad due to the association of Reye syndrome with salicylate therapy and wild-type varicella infection [see *Drug Interactions* (7.2) and *Patient Counseling Information* (17)].

6 ADVERSE REACTIONS

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a vaccine cannot be directly compared to rates in the clinical trials of another vaccine and may not reflect the rates observed in practice. Vaccine-related adverse reactions reported during clinical trials were assessed by the study investigators to be possibly, probably, or definitely vaccine-related and are summarized below.

Children 12 Through 23 Months of Age Who Received a Single Dose of ProQuad

ProQuad was administered subcutaneously to 4497 children 12 through 23 months of age involved in 4 randomized clinical trials without concomitant administration with other vaccines. The safety of ProQuad was compared with the safety of M-M-R II and VARIVAX given concomitantly (N=2038) at separate injection sites. The safety profile for ProQuad was similar to the component vaccines. Children in these studies were monitored for up to 42 days postvaccination using vaccination report card-aided surveillance. Safety follow-up was obtained for 98% of children in each group. Few subjects (<0.1%) who received ProQuad

discontinued the study due to an adverse reaction. The race distribution of the study subjects across these studies following a first dose of ProQuad was as follows: 65.2% White; 13.1% African-American; 11.1% Hispanic; 5.8% Asian/Pacific; 4.5% other; and 0.2% American Indian. The racial distribution of the control group was similar to that of the group who received ProQuad. The gender distribution across the studies following a first dose of ProQuad was 52.5% male and 47.5% female. The gender distribution of the control group was similar to that of the group who received ProQuad. Vaccine-related injection-site and systemic adverse reactions observed among recipients of ProQuad or M-M-R II and VARIVAX at a rate of at least 1% are shown in Table 1. Systemic vaccine-related adverse reactions that were reported at a significantly greater rate in individuals who received a first dose of ProQuad than in individuals who received first doses of M-M-R II and VARIVAX concomitantly at separate injection sites were fever ($\geq 102^{\circ}\text{F}$ [$\geq 38.9^{\circ}\text{C}$] oral equivalent or abnormal) (21.5% versus 14.9%, respectively, risk difference 6.6%, 95% CI: 4.6, 8.5), and measles-like rash (3.0% versus 2.1%, respectively, risk difference 1.0%, 95% CI: 0.1, 1.8). Both fever and measles-like rash usually occurred within 5 to 12 days following the vaccination, were of short duration, and resolved with no long-term sequelae. Pain/tenderness/soreness at the injection site was reported at a statistically lower rate in individuals who received ProQuad than in individuals who received M-M-R II and VARIVAX concomitantly at separate injection sites (22.0% versus 26.8%, respectively, risk difference -4.8%, 95% CI: -7.1, -2.5). The only vaccine-related injection-site adverse reaction that was more frequent among recipients of ProQuad than recipients of M-M-R II and VARIVAX was rash at the injection site (2.4% versus 1.6%, respectively, risk difference 0.9%, 95% CI: 0.1, 1.5).

Table 1: Vaccine-Related Injection-Site and Systemic Adverse Reactions Reported in $\geq 1\%$ of Children Who Received ProQuad Dose 1 or M-M-R II and VARIVAX at 12 to 23 Months of Age (0 to 42 Days Postvaccination)

Adverse Reactions	ProQuad (N=4497) (n=4424)	M-M-R II and VARIVAX (N=2038) (n=1997)
	%	%
<i>Injection Site*</i>		
Pain/tenderness/soreness [†]	22.0	26.7
Erythema [†]	14.4	15.8
Swelling [†]	8.4	9.8
Ecchymosis	1.5	2.3
Rash	2.3	1.5
<i>Systemic</i>		
Fever ^{†,‡}	21.5	14.9
Irritability	6.7	6.7
Measles-like rash [†]	3.0	2.1
Varicella-like rash [†]	2.1	2.2
Rash (not otherwise specified)	1.6	1.4
Upper respiratory infection	1.3	1.1
Viral exanthema	1.2	1.1
Diarrhea	1.2	1.3

* Injection-site adverse reactions for M-M-R II and VARIVAX are based on occurrence with either of the vaccines administered.

[†] Designates a solicited adverse reaction. Injection-site adverse reactions were solicited only from Days 0 to 4 postvaccination.

[‡] Temperature reported as elevated ($\geq 102^{\circ}\text{F}$, oral equivalent) or abnormal.

N = number of subjects vaccinated.

n = number of subjects with safety follow-up.

Rubella-like rashes were observed in $<1\%$ of subjects following a first dose of ProQuad.

In these clinical trials, two cases of herpes zoster were reported among 2108 healthy subjects 12 through 23 months of age who were vaccinated with their first dose of ProQuad and followed for 1 year. Both cases were unremarkable and no sequelae were reported.

Children 15 to 31 Months of Age Who Received a Second Dose of ProQuad

In 5 clinical trials, 2780 healthy children were vaccinated subcutaneously with ProQuad (dose 1) at 12 to 23 months of age and then administered a second dose approximately 3 to 9 months later. The race distribution of the study subjects across these studies following a second dose of ProQuad was as follows: 64.4% White; 14.1% African-American; 12.0% Hispanic; 5.9% other; 3.5% Asian/Pacific; and 0.1% American Indian. The gender distribution across the studies following a second dose of ProQuad was 51.5% male and 48.5% female. Children in these open-label studies were monitored for at least 28 days

postvaccination using vaccination report card-aided surveillance. Safety follow-up was obtained for approximately 97% of children overall. Vaccine-related injection-site and systemic adverse reactions observed after Dose 1 and 2 of ProQuad at a rate of at least 1% are shown in Table 2. In these trials, the overall rates of systemic adverse reactions after ProQuad (dose 2) were comparable to, or lower than, those seen with the first dose. In the subset of children who received both ProQuad dose 1 and dose 2 in these trials (N=2408) with follow-up for fever, fever $\geq 102.2^{\circ}\text{F}$ ($\geq 38.9^{\circ}\text{C}$) was observed significantly less frequently days 1 to 28 after the second dose (10.8%) than after the first dose (19.1%) (risk difference 8.3%, 95% CI: 6.4, 10.3). Fevers $\geq 102.2^{\circ}\text{F}$ ($\geq 38.9^{\circ}\text{C}$) days 5 to 12 after vaccinations were also reported significantly less frequently after dose 2 (3.9%) than after dose 1 (13.6%) (risk difference 9.7%, 95% CI: 8.1, 11.3). In the subset of children who received both doses and for whom injection-site reactions were reported (N=2679), injection-site erythema was noted significantly more frequently after ProQuad (dose 2) as compared to ProQuad (dose 1) (12.6% and 10.8%, respectively, risk difference -1.8, 95% CI: -3.3, -0.3); however, pain and tenderness at the injection site was significantly lower after dose 2 (16.1%) as compared with after dose 1 (21.9%) (risk difference, 5.8%, 95% CI: 4.1, 7.6). Two children had febrile seizures after ProQuad (dose 2); both febrile seizures were thought to be related to a concurrent viral illness [see *Adverse Reactions* (6.3) and *Clinical Studies* (14)]. These studies were not designed or statistically powered to detect a difference in rates of febrile seizure between recipients of ProQuad as compared to M-M-R II and VARIVAX. The risk of febrile seizure has not been evaluated in a clinical study comparing the incidence rate after ProQuad (dose 2) with the incidence rate after concomitant M-M-R II (dose 2) and VARIVAX (dose 2) [see *Adverse Reactions* (6.1), *Children 4 to 6 Years of Age Who Received ProQuad After Primary Vaccination with M-M-R II and VARIVAX*].

Table 2: Vaccine-Related Injection-Site and Systemic Adverse Reactions Reported in $\geq 1\%$ of Children Who Received ProQuad Dose 1 at 12 to 23 Months of Age and Dose 2 at 15 to 31 Months of Age (1 to 28 Days Postvaccination)

Adverse Reactions	ProQuad Dose 1 (N=3112) (n=3019) %	ProQuad Dose 2 (N=2780) (n=2695) %
<i>Injection-Site</i>		
Pain/tenderness/soreness*	21.4	15.9
Erythema*	10.7	12.4
Swelling*	8.0	8.5
Injection-site bruising	1.1	0.0
<i>Systemic</i>		
Fever* [†]	20.4	8.3
Irritability	6.0	2.4
Measles-like/Rubella-like rash	4.3	0.9
Varicella-like/Vesicular rash	1.5	0.1
Diarrhea	1.3	0.6
Upper respiratory infection	1.3	1.4
Rash (not otherwise specified)	1.2	0.6
Rhinorrhea	1.1	1.0

* Designates a solicited adverse reaction. Injection-site adverse reactions were solicited only from Days 1 to 5 postvaccination.

[†] Temperature reported as elevated or abnormal.

N = number of subjects vaccinated.

n = number of subjects with safety follow-up.

Children 4 to 6 Years of Age Who Received ProQuad After Primary Vaccination with M-M-R II and VARIVAX

In a double-blind clinical trial, 799 healthy 4- to 6-year-old children who received M-M-R II and VARIVAX at least 1 month prior to study entry were randomized to receive ProQuad administered subcutaneously and placebo (N=399), M-M-R II and placebo concomitantly (N=205) at separate injection sites, or M-M-R II and VARIVAX (N=195) concomitantly at separate injection sites [see *Clinical Studies (14)*]. Children in these studies were monitored for up to 42 days postvaccination using vaccination report card-aided surveillance. Safety follow-up was obtained for >98% of children in each group. The race distribution of the study subjects following a dose of ProQuad was as follows: 78.4% White; 12.3% African-American; 3.8% Hispanic; 3.5% other; and 2.0% Asian/Pacific. The gender distribution following a dose of ProQuad was 52.1% male and 47.9% female. Injection-site and systemic adverse reactions observed after Dose 1 and 2 of ProQuad at a rate of at least 1% are shown in Table 3 [see *Clinical Studies (14)*].

Table 3: Vaccine-Related Injection-Site and Systemic Adverse Reactions Reported in ≥1% of Children Previously Vaccinated with M-M-R II and VARIVAX Who Received ProQuad + Placebo, M-M-R II + Placebo, or M-M-R II + VARIVAX at 4 to 6 Years of Age (1 to 43 Days Postvaccination)

Adverse Reactions	ProQuad + Placebo (N=399) (n=397) %		M-M-R II + Placebo (N=205) (n=205) %		M-M-R II + VARIVAX (N=195) (n=193) %	
<i>Systemic</i>						
Fever*†	2.5		2.0		4.1	
Cough	1.3		0.5		0.5	
Irritability	1.0		0.5		1.0	
Headache	0.8		1.5		1.6	
Rhinorrhea	0.5		1.0		0.5	
Nasopharyngitis	0.3		1.0		1.0	
Vomiting	0.3		1.0		0.5	
Upper respiratory infection	0.0		0.0		1.0	
	ProQuad %	Placebo %	M-M-R II %	Placebo %	M-M-R II %	VARIVAX %
<i>Injection-Site</i>						
Pain*	41.1	34.5	36.6	34.1	35.2	36.8
Erythema*	24.4	13.4	15.6	14.1	14.5	15.5
Swelling*	15.6	8.1	10.2	8.8	7.8	10.9
Bruising	3.5	3.8	2.4	3.4	1.6	2.1
Rash	1.5	1.3	0.0	0.0	0.5	0.0
Pruritus	1.0	0.3	0.0	0.0	0.0	1.0
Nodule	0.0	0.0	0.0	0.0	0.0	1.0

* Designates a solicited adverse reaction. Injection-site adverse reactions were solicited only from Days 1 to 5 postvaccination.

† Temperature reported as elevated (≥102°F, oral equivalent) or abnormal.

N = number of subjects vaccinated.

n = number of subjects with safety follow-up.

Safety in Trials That Evaluated Concomitant Use with Other Vaccines

ProQuad Administered with Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (DTaP) and Haemophilus influenzae type b Conjugate (Meningococcal Protein Conjugate) and Hepatitis B (Recombinant) Vaccine

In an open-label clinical trial, 1434 children were randomized to receive ProQuad administered subcutaneously given with diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed (DTaP) and *Haemophilus influenzae* type b conjugate (meningococcal protein conjugate) and hepatitis B (recombinant) vaccine concomitantly (N=949) or non-concomitantly with ProQuad given first and the other vaccines 6 weeks later (N=485). No clinically significant differences in adverse events were reported between treatment groups [see *Clinical Studies (14)*]. The race distribution of the study subjects who received ProQuad was as follows: 70.7% White; 10.9% Asian/Pacific; 10.7% African-American; 4.5% Hispanic; 3.0% other; and 0.2% American Indian. The gender distribution of the study subjects who received ProQuad was 53.6% male and 46.4% female.

ProQuad Administered with Pneumococcal 7-valent Conjugate Vaccine and/or Hepatitis A Vaccine, Inactivated

In an open-label clinical trial, 1027 healthy children 12 to 23 months of age were randomized to receive ProQuad administered subcutaneously (dose 1) and pneumococcal 7-valent conjugate vaccine (dose 4) concomitantly (N=510) or non-concomitantly at different clinic visits (N=517). The race distribution of the study subjects was as follows: 65.2% White; 15.1% African-American; 10.0% Hispanic; 6.6% other; and 3.0% Asian/Pacific. The gender distribution of the study subjects was 54.5% male and 45.5% female. Injection-site and systemic adverse reactions observed among recipients of ProQuad administered concomitantly or non-concomitantly with pneumococcal 7-valent conjugate vaccine at a rate of at least 1% are shown in Table 4. No clinically significant differences in adverse reactions were reported between the concomitant and non-concomitant treatment groups [see *Clinical Studies (14)*].

Table 4: Vaccine-Related Injection-Site and Systemic Adverse Reactions
Reported in ≥1% of Children Who Received ProQuad (dose 1) Concomitantly or Non-Concomitantly with PCV7* (dose 4) at the First Visit (1 to 28 Days Postvaccination)

Adverse Reactions	ProQuad + PCV7 (N=510) (n=498) %	PCV7 (N=258) (n=250) %	ProQuad (N=259) (n=255) %
<i>Injection-Site - ProQuad</i>			
Pain [†]	24.9	N/A	24.7
Erythema [†]	12.4	N/A	11.0
Swelling [†]	10.8	N/A	7.5
Bruising	2.0	N/A	1.6
<i>Injection-Site - PCV7</i>			
Pain [†]	30.5	29.6	N/A
Erythema [†]	21.1	24.4	N/A
Swelling [†]	17.9	20.0	N/A
Bruising	1.6	1.2	N/A
<i>Systemic</i>			
Fever ^{†,‡}	15.5	10.0	15.3
Measles-like rash	4.4	0.8	5.1
Irritability	3.8	3.6	3.5
Upper respiratory infection	1.6	0.8	1.2
Varicella-like/vesicular rash	1.6	0.0	1.2
Diarrhea	0.8	1.2	1.2
Vomiting	0.6	0.8	1.2
Rash	0.4	0.0	1.2
Somnolence	0.0	0.0	1.2

* PCV7 = Pneumococcal 7-valent conjugate vaccine, dose 4.

[†] Designates a solicited adverse reaction. Injection-site adverse reactions were solicited only from Days 1 to 5 postvaccination.

[‡] Temperature reported as elevated (≥102°F, oral equivalent) or abnormal.

N/A = Not applicable.

N = number of subjects vaccinated.

n = number of subjects with safety follow-up.

In an open-label clinical trial, 699 healthy children 12 to 23 months of age were randomized to receive 2 doses of VAQTA (hepatitis A vaccine, inactivated) (N=352) or 2 doses of VAQTA concomitantly with 2 doses of ProQuad administered subcutaneously (N=347) at least 6 months apart. An additional 1101 subjects received 2 doses of VAQTA alone at least 6 months apart (non-randomized), resulting in 1453 subjects receiving 2 doses of VAQTA alone (1101 non-randomized and 352 randomized) and 347 subjects receiving 2 doses of VAQTA concomitantly with ProQuad (all randomized). The race distribution of the study subjects following a dose of ProQuad was as follows: 47.3% White; 42.7% Hispanic; 5.5% other; 2.9% African-American; and 1.7% Asian/Pacific. The gender distribution of the study subjects following a dose of ProQuad was 49.3% male and 50.7% female. Vaccine-related injection-site adverse reactions (days 1 to 5 postvaccination) and systemic adverse events (days 1 to 14 post VAQTA and days 1 to 28 post ProQuad vaccination) observed among recipients of VAQTA and ProQuad administered concomitantly with VAQTA at a rate of at least 1% are shown in Tables 5 and 6, respectively. In addition, among the randomized cohort, in the 14 days after each vaccination, the rates of fever (including all vaccine- and non-vaccine-related reports) were significantly higher in subjects who received ProQuad with VAQTA concomitantly after dose 1 (22.0%) as compared to subjects given dose 1 of VAQTA without ProQuad (10.8%). However, rates of fever were not significantly higher in subjects who received ProQuad with VAQTA concomitantly after dose 2 (12.5%) as compared to subjects given dose 2 of VAQTA without

ProQuad (9.4%). In post-hoc analyses, these rates were significantly different for dose 1 (relative risk (RR) 2.03 [95% CI: 1.42, 2.94]), but not dose 2 (RR 1.32 [95% CI: 0.82, 2.13]). Rates of injection-site adverse reactions and other systemic adverse events were lower following a second dose than following the first dose of both vaccines given concomitantly.

Table 5: Vaccine-Related Injection-Site Adverse Reactions
Reported in ≥1% of Children Who Received VAQTA or ProQuad Concomitantly with VAQTA
1 to 5 Days After Vaccination with VAQTA or VAQTA and ProQuad

Adverse Reactions	Dose 1		Dose 2	
	VAQTA (N=1453) (n=1412) %	ProQuad + VAQTA (N=347) (n=328) %	VAQTA (N=1301) (n=1254) %	ProQuad + VAQTA (N=292) (n=264) %
<i>Injection-Site - VAQTA</i>				
Pain/tenderness*	29.2	27.1	30.1	25.0
Erythema*	13.5	12.5	14.3	11.7
Swelling*	7.1	9.1	9.0	8.0
Injection-site bruising	1.9	2.4	1.0	0.8
<i>Injection-Site - ProQuad</i>				
Pain/tenderness*	N/A	30.5	N/A	26.2
Erythema*	N/A	13.4	N/A	12.9
Swelling*	N/A	6.7	N/A	6.5
Injection-site bruising	N/A	1.5	N/A	0.4

* Designates a solicited adverse reaction. Injection-site adverse reactions were solicited only from Days 1 to 5 postvaccination.

N/A = Not applicable.

N = number of subjects vaccinated.

n = number of subjects with safety follow-up.

Table 6: Vaccine-Related Systemic Adverse Reactions
Reported in ≥1% of Children Who Received VAQTA* or ProQuad Concomitantly with VAQTA
1 to 14 Days After VAQTA or Vaccination with ProQuad and VAQTA and 1 to 28 Days After Vaccination with ProQuad
and VAQTA

Adverse Reactions	Dose 1			Dose 2		
	Days 1 to 14		Days 1 to 28	Days 1 to 14		Days 1 to 28
	VAQTA [†] (N=1453) (n=1412) %	ProQuad + VAQTA [†] (N=347) (n=328) %	ProQuad + VAQTA (N=347) (n=328) %	VAQTA (N=1301) (n=1254) %	ProQuad + VAQTA [†] (N=292) (n=264) %	ProQuad + VAQTA [†] (N=291) (n=263) %
Fever ^{‡,§}	5.7	14.9	15.2	4.1	8.0	8.4
Irritability	5.8	7.0	7.3	3.5	5.3	5.3
Measles-like rash	0.0	3.4	3.4	0.0	1.1	1.1
Rhinorrhea	0.6	2.7	3.0	0.6	1.1	2.7
Diarrhea	1.5	1.8	2.4	1.7	0.4	0.8
Cough	0.6	2.1	2.1	0.2	0.8	1.5
Vomiting	1.1	0.3	0.9	0.6	0.8	1.1

* Systemic adverse events for subjects given VAQTA alone were collected for 14 days postvaccination.

[†] Safety follow-up for systemic adverse reactions was 14 days for VAQTA and 28 days for ProQuad + VAQTA.

[‡] Designates a solicited adverse reaction.

[§] Temperature reported as elevated or abnormal.

N = number of subjects vaccinated.

n = number of subjects with safety follow-up.

In an open-label clinical trial, 653 children 12 to 23 months of age were randomized to receive a first dose of ProQuad administered subcutaneously with VAQTA and pneumococcal 7-valent conjugate vaccine concomitantly (N=330) or a first dose of ProQuad administered subcutaneously and pneumococcal 7-valent conjugate vaccine concomitantly and then vaccinated with VAQTA 6 weeks later (N=323). Approximately 6 months later, subjects received either the second doses of ProQuad and VAQTA concomitantly or the second doses of ProQuad and VAQTA separately. The race distribution of the study subjects was as follows: 60.3% White; 21.6% African-American; 9.5% Hispanic; 7.2% other; 1.1% Asian/Pacific; and 0.3%

American Indian. The gender distribution of the study subjects was 50.7% male and 49.3% female. Vaccine-related injection-site and systemic adverse reactions observed among recipients of concomitant ProQuad, VAQTA, and pneumococcal 7-valent conjugate vaccine and ProQuad and pneumococcal 7-valent conjugate vaccine at a rate of at least 1% are shown in Tables 7 and 8. In the 28 days after vaccination with the first dose of ProQuad, the rates of fever (including all vaccine- and non-vaccine-related reports) were comparable in subjects who received the 3 vaccines together (38.6%) as compared with subjects given ProQuad and pneumococcal 7-valent conjugate vaccine (42.7%). The rates of fever in the 28 days following the second dose of ProQuad were also comparable in subjects who received ProQuad and VAQTA together (17.4%) as compared with subjects given ProQuad separately from VAQTA (17.0%). In a post-hoc analysis, these differences were not statistically significant after ProQuad (dose 1) (RR 0.90 [95% CI: 0.75, 1.09]) nor after dose 2 (RR 1.02 [95% CI: 0.70, 1.51]). No clinically significant differences in adverse reactions were reported among treatment groups [see *Clinical Studies* (14)].

Table 7: Vaccine-Related Injection-Site Adverse Reactions
Reported in ≥1% of Children Who Received ProQuad + VAQTA + PCV7* Concomitantly or VAQTA Alone Followed by ProQuad + PCV7 Concomitantly (1 to 5 Days After a Dose of ProQuad)

Adverse Reactions	Dose 1		Dose 2	
	VAQTA + ProQuad + PCV7 (N=330) (n=311) %	VAQTA Alone Followed by ProQuad + PCV7 (N=323) (n=302) %	VAQTA + ProQuad (N=273) (n=265) %	VAQTA Alone Followed by ProQuad (N=240) (n=230) %
<i>Injection-Site - ProQuad</i>				
Pain/tenderness†	21.2	24.2	18.1	17.0
Erythema†	13.5	11.9	10.6	13.0
Swelling†	7.4	10.9	8.3	11.7
Bruising	1.9	1.3	0.8	0.4
<i>Injection-Site - VAQTA</i>				
Pain/tenderness†	20.6	15.3	17.5	20.3
Erythema†	9.6	11.7	9.1	12.7
Swelling†	6.8	9.5	6.1	7.6
Bruising	1.3	1.1	1.1	1.6
Rash	1.0	0.0	0.4	0.4
<i>Injection-Site - PCV7</i>				
Pain/tenderness†	25.4	27.6	N/A	N/A
Erythema†	16.4	16.6	N/A	N/A
Swelling†	13.2	14.3	N/A	N/A
Bruising	0.6	1.7	N/A	N/A

* PCV7 = Pneumococcal 7-valent conjugate vaccine.

† Designates a solicited adverse reaction. Injection-site adverse reactions were solicited only from Days 1 to 5 postvaccination at each vaccine injection site.

N/A = Not applicable.

N = number of subjects vaccinated.

n = number of subjects with safety follow-up.

Table 8: Vaccine-Related Systemic Adverse Reactions
Reported in ≥1% of Children Who Received ProQuad + VAQTA + PCV7* Concomitantly, or VAQTA Alone Followed by ProQuad + PCV7 Concomitantly (1 to 28 Days After a Dose of ProQuad)

Adverse Reactions	Dose 1		Dose 2	
	VAQTA + ProQuad + PCV7 (N=330) (n=311) %	VAQTA Alone Followed by ProQuad + PCV7 (N=323) (n=302) %	VAQTA + ProQuad (N=273) (n=265) %	VAQTA Alone Followed by ProQuad (N=240) (n=230) %
Fever†,‡	26.4	27.2	9.1	9.6
Irritability	4.8	6.3	1.9	1.3
Measles-like rash†	2.3	4.0	0.0	0.0
Varicella-like rash†	1.0	1.7	0.0	0.0
Rash (not otherwise specified)	1.3	1.3	0.0	0.9
Diarrhea	1.3	1.3	0.4	1.3

Upper respiratory infection	1.0	1.3	1.1	0.9
Viral infection	1.0	0.7	0.0	0.0
Rhinorrhea	0.0	0.7	1.1	0.0

* PCV7 = Pneumococcal 7-valent conjugate vaccine.

† Designates a solicited adverse reaction.

‡ Temperature reported as elevated or abnormal.

N = number of subjects vaccinated.

n = number of subjects with safety follow-up.

In a randomized open-label clinical trial (NCT00402831), conducted in France, 405 children 12 months through 18 months of age received 2 doses of ProQuad, administered 30 days apart (a non-US licensed interval), by either the intramuscular (n=202) or subcutaneous (n=203) route. In the overall population, 50.9% were male and the median age was 13.3 months. Local and systemic solicited adverse reactions were recorded by parents or guardians using standardized diary cards. Local solicited reactions were recorded for 4 days after vaccination, and systemic solicited adverse reactions were recorded for 28 days after vaccination. In the event that a participant experienced a rash or a mumps-like illness, parents and/or guardians were instructed to contact the investigator for an examination as soon as possible and no later than 72 hours following onset of symptoms. The nature of any rash was characterized by principal investigator either as measles-like, rubella-like, varicella-like or “other”. Study investigators reviewed the diary card with the participant or participant’s legal guardian 30 days and 42 days after dose 1 and dose 2, respectively to ensure consistency with protocol definitions. Tables 9 and 10 below present the frequency of solicited adverse reactions based on the final assessment by the study investigators.

Table 9. Proportion of Participants Reporting Solicited Adverse Reactions Following First Vaccination with ProQuad, by the Intramuscular or Subcutaneous Route

	INTRAMUSCULAR N=202 %	SUBCUTANEOUS N=203 %
Solicited local injection-site adverse reactions (Days 0 to 4)*		
Erythema†	5.0	14.3
Mild	4.5	12.8
Moderate	0	1.5
Severe	0	0
Missing	0.5	0
Pain‡	10.9	5.9
Mild	8.9	3.9
Moderate	2.0	2.0
Severe	0	0
Swelling†	1.0	3.9
Mild	1.0	3.9
Moderate	0	0
Severe	0	0
Solicited systemic adverse reactions (Days 0 to 28)		
Measles/Measles-like rash	0.5	2.0

Rubella/Rubella-like rash	3.0	3.0
Varicella/Varicella-like rash	1.0	0.5
Zoster/Zoster-like rash	0	0
Mumps-like illness	0.5	0
Fever (temperature $\geq 38.0^{\circ}\text{C}$) ^{§,¶}	62.8	68.3
38.0-38.5°C	21.1	17.6
>38.5-39.0°C	18.1	21.6
>39.0-39.5°C	14.1	18.1
>39.5-40.0°C	7.0	9.0
>40.0°C	2.5	2.0

N=total number of participants in the group

* Post-dose 1 (0-28 days), there was one episode of an injection-site rubella-like rash and one injection-site varicella-like rash. They were both reported in the subcutaneous group.

† Intensity of injection site reaction: mild or ≤ 2.5 cm; moderate or >2.5 to ≤ 5.0 cm; severe or >5.0 cm.

‡ Intensity of pain: mild: awareness of symptom but easily tolerated; moderate: definitely acting like something is wrong; severe: extremely distressed or unable to do usual activities.

§ The percentage of fever is defined within the population who had valid temperature measurements. Three participants in IM group and four participants in SC group do not have temperature measurements and were excluded from the denominator; resulting in N=199 and N=199, respectively.

¶ In the IM Group 96.0% of fevers were documented using the rectal route of measurement and 4.0% of fevers were documented only by the axillary route of measurement. In the SC Group 99.3% of fevers were documented using the rectal route of measurement and 0.7% of fevers were documented only by the axillary route of measurement.

Table 10. Proportion of Participants Reporting Solicited Adverse Reactions Following Second Vaccination with ProQuad, by the Intramuscular or Subcutaneous Route

	INTRAMUSCULAR N=201 %	SUBCUTANEOUS N=200 %
Solicited local injection-site adverse reactions (Days 0 to 4)*		
Erythema [†]	15.4	27.0
Mild	13.9	22.5
Moderate	1.0	4.5
Severe	0	0
Missing	0.5	0
Pain [‡]	10.0	10.0
Mild	9.0	7.0
Moderate	0.5	3.0
Severe	0.5	0
Swelling [‡]	6.0	12.5
Mild	5.0	11.0

Moderate	1.0	1.0
Severe	0	0
Missing	0	0.5% (1/200)
Solicited systemic adverse reactions (Days 0 to 28)		
Measles-like rash	0	1.0
Rubella-like rash	2.0	1.0
Varicella-like rash	0	2.0
Zoster-like rash	0	0
Mumps-like illness	0.5	0
Fever (temperature $\geq 38.0^{\circ}\text{C}$) ^{§,¶}	50.0	47.2
38.0-38.5°C	13.8	16.4
>38.5-39.0°C	18.4	10.8
>39.0-39.5°C	11.2	11.3
>39.5-40.0°C	5.6	7.2
>40.0°C	1.0	1.5

N=total number of participants in the group

* Post-dose 2 (0-28 days), there was only 1 episode of an injection-site measles-like rash and this was reported in the subcutaneous group.

† Intensity of injection site reaction: mild or ≤ 2.5 cm; moderate or >2.5 to ≤ 5.0 cm; severe or >5.0 cm.

‡ Intensity of pain: mild: awareness of symptom but easily tolerated; moderate: definitely acting like something is wrong; severe: extremely distressed or unable to do usual activities.

§ The percentage of fever is defined within the population who had valid temperature measurements. Five participants in IM group and five participants in SC group did not have temperature measurements and were excluded from the denominator; resulting in N=196 and N=195, respectively.

¶ In the IM Group 95.9% of fevers were documented using the rectal route of measurement and 4.1% of fevers were documented only by the axillary route of measurement. In the SC Group 98.9% of fevers were documented using the rectal route of measurement and 1.1% of fevers were documented only by the axillary route of measurement.

Unsolicited adverse events (0-28 days post-vaccination 1 and 2) and serious adverse events (day 0 to last visit) were recorded using diary cards supplemented by medical review. Data on unsolicited adverse events were transcribed into the study database during an on-site visit at day 30 and day 42. Serious adverse events occurred at a rate of 1% and 0.5% in each group post-dose 1 and 2, respectively. None of the serious adverse events that occurred were considered related to the study vaccination.

Herpes Zoster

ProQuad and VARIVAX each contain the Oka/Merck varicella virus vaccine strain. Clinical trial data with VARIVAX are therefore, relevant to ProQuad. Overall, 9454 healthy children (12 months to 12 years of age) and 1648 adolescents and adults (13 years of age and older) have been vaccinated with VARIVAX in clinical trials. Eight cases of herpes zoster have been reported in children during 42,556 person-years of follow-up in clinical trials, resulting in a calculated incidence of at least 18.8 cases per 100,000 person-years. The completeness of this reporting has not been determined. One case of herpes zoster has been reported in the adolescent and adult age group during 5410 person-years of follow-up in clinical trials, resulting in a calculated incidence of 18.5 cases per 100,000 person-years. All 9 cases were mild and without sequelae. Two cultures (one child and one adult) obtained from vesicles were positive for wild-type VZV as confirmed by restriction endonuclease analysis {11}. The long-term effect of VARIVAX on the

incidence of herpes zoster, particularly in those vaccinees exposed to wild-type varicella, is unknown at present.

In children, the reported rate of herpes zoster in VARIVAX recipients appears not to exceed that previously determined in a population-based study of healthy children who had experienced wild-type varicella {12}. The incidence of herpes zoster in adults who have had wild-type varicella infection is higher than that in children.

6.2 Post-Marketing Experience

The following adverse events have been identified during post-approval use of either the components of ProQuad or ProQuad. Because the events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to vaccine exposure.

Infections and infestations

Subacute sclerosing panencephalitis, encephalitis, aseptic meningitis, meningitis, measles, atypical measles, pneumonia, respiratory infection, infection, varicella (vaccine strain), influenza, wild-type or vaccine strain herpes zoster, orchitis, epididymitis, cellulitis, skin infection, retinitis, bronchitis, parotitis, sinusitis, impetigo, herpes simplex, candidiasis, rhinitis.

The vaccine virus (Oka/Merck strain) contained in ProQuad may establish latency of varicella zoster virus in immunocompetent individuals, with the potential for later development of herpes zoster.

Cases of encephalitis or meningitis caused by vaccine strain varicella virus have been reported in immunocompromised and immunocompetent individuals previously vaccinated with VARIVAX (same varicella vaccine strain as in ProQuad) months to years after vaccination. Reported cases were commonly associated with preceding or concurrent herpes zoster rash.

Blood and the lymphatic system disorders

Aplastic anemia, thrombocytopenia, regional lymphadenopathy, lymphadenitis.

Immune system disorders

Anaphylaxis and related phenomena such as angioneurotic edema, facial edema, and peripheral edema, anaphylactoid reaction.

Psychiatric disorders

Agitation, apathy, nervousness.

Nervous system disorders

Measles inclusion body encephalitis, acute disseminated encephalomyelitis, transverse myelitis, cerebrovascular accident, encephalopathy, Guillain-Barré syndrome, optic neuritis, Bell's palsy, polyneuropathy, ataxia, hypersomnia, afebrile convulsions or seizures, febrile seizure, headache, syncope, dizziness, tremor, paresthesia.

Eye disorders

Necrotizing retinitis (in immunocompromised individuals), retrobulbar neuritis, ocular palsies, edema of the eyelid, irritation eye.

Ear and labyrinth disorders

Nerve deafness, ear pain.

Vascular disorders

Extravasation blood.

Respiratory, thoracic and mediastinal disorders

Pneumonitis, pulmonary congestion, wheezing, bronchial spasm, epistaxis, sore throat.

Gastrointestinal disorders

Hematochezia, abdominal pain, mouth ulcer.

Skin and subcutaneous tissue disorders

Stevens-Johnson syndrome, Henoch-Schönlein purpura, erythema multiforme, acute hemorrhagic edema of infancy, purpura, skin induration, panniculitis, pruritus.

Musculoskeletal, connective tissue and bone disorders

Arthritis, arthralgia, pain of the hip, leg, or neck; myalgia; musculoskeletal pain.

General disorders and administration site conditions

Injection-site complaints including wheal and flare, warm to touch, stiffness, warm sensation, inflammation, injection-site hemorrhage, injection-site injury.

Herpes Zoster

The vaccine virus (Oka/Merck strain) contained in ProQuad may establish latency of varicella zoster virus in immunocompetent individuals, with the potential for later development of herpes zoster.

6.3 Post-Marketing Observational Safety Surveillance Study

Safety was evaluated in an observational study that included 69,237 children vaccinated with ProQuad 12 months to 12 years old. A historical comparison group included 69,237 age-, gender-, and date-of-vaccination- (day and month) matched subjects who were given M-M-R II and VARIVAX concomitantly. The primary objective was to assess the incidence of febrile seizures occurring within various time intervals after vaccination in 12- to 60-month-old children who had neither been vaccinated against measles, mumps, rubella, or varicella, nor had a history of the wild-type infections (N=31,298 vaccinated with ProQuad, including 31,043 who were 12 to 23 months old). The incidence of febrile seizures was also assessed in a historical control group of children who had received their first vaccination with M-M-R II and VARIVAX concomitantly (N=31,298, including 31,019 who were 12 to 23 months old). The secondary objective was to assess the general safety of ProQuad in the 30-day period after vaccination in children 12 months to 12 years old.

In pre-licensure clinical studies, an increase in fever was observed 5 to 12 days after vaccination with ProQuad (dose 1) compared to M-M-R II and VARIVAX (dose 1) given concomitantly. In the post-marketing observational surveillance study, results from the primary safety analysis revealed an approximate two-fold increase in the risk of febrile seizures in the same 5 to 12 day timeframe after vaccination with ProQuad (dose 1). The incidence of febrile seizures 5 to 12 days after ProQuad (dose 1) (0.70 per 1000 children) was higher than that in children receiving M-M-R II and VARIVAX concomitantly (0.32 per 1000 children) [RR 2.20, 95% confidence interval (CI): 1.04, 4.65]. The incidence of febrile seizures 0 to 30 days after ProQuad (dose 1) (1.41 per 1000 children) was similar to that observed in children receiving M-M-R II and VARIVAX concomitantly [RR 1.10 (95% CI: 0.72, 1.69)]. See Table 11. General safety analyses revealed that the risks of fever (RR=1.89; 95% CI: 1.67, 2.15) and skin eruption (RR=1.68; 95% CI: 1.07, 2.64) were significantly higher after ProQuad (dose 1) compared with those who received concomitant first doses of M-M-R II and VARIVAX, respectively. All medical events that resulted in hospitalization or emergency room visits were compared between the group given ProQuad and the historical comparison group, and no other safety concerns were identified in this study.

Table 11: Confirmed Febrile Seizures Days 5 to 12 and 0 to 30 After Vaccination with ProQuad (dose 1) Compared to Concomitant Vaccination with M-M-R II and VARIVAX (dose 1) in Children 12 to 60 Months of Age

Time Period	ProQuad cohort (N=31,298)		MMR+V cohort (N=31,298)		Relative risk (95% CI)
	n	Incidence per 1000	n	Incidence per 1000	
5 to 12 Days	22	0.70	10	0.32	2.20 (1.04, 4.65)
0 to 30 Days	44	1.41	40	1.28	1.10 (0.72, 1.69)

In this observational post-marketing study, no case of febrile seizure was observed during the 5 to 12 day postvaccination time period among 26,455 children who received ProQuad as a second dose of M-M-R II and VARIVAX. In addition, detailed general safety data were available from more than 25,000 children who received ProQuad as a second dose of M-M-R II and VARIVAX, most of them (95%) between 4 and 6 years of age, and an analysis of these data by an independent, external safety monitoring committee did not identify any specific safety concern.

7 DRUG INTERACTIONS

7.1 Immune Globulins and Transfusions

Administration of immune globulins and other blood products concurrently with ProQuad vaccine may interfere with the expected immune response [see *Warnings and Precautions* (5.7)] {9-11}. The ACIP has specific recommendations for intervals between administration of antibody containing products and live virus vaccines.

7.2 Salicylates

Reye syndrome has been reported following the use of salicylates during wild-type varicella infection. Vaccine recipients should avoid use of salicylates for 6 weeks after vaccination with ProQuad [see *Warnings and Precautions* (5.8) and *Patient Counseling Information* (17)].

7.3 Corticosteroids and Immunosuppressive Drugs

ProQuad vaccine should not be administered to individuals receiving immunosuppressive therapy, including high dose corticosteroids. Vaccination with ProQuad vaccine can result in disseminated disease and extensive vaccine-associated rash in individuals on immunosuppressive drugs [see *Contraindications (4.2)*].

7.4 Drug/Laboratory Test Interactions

Live, attenuated measles, mumps, and rubella virus vaccines given individually may result in a temporary depression of tuberculin skin sensitivity. Therefore, if a tuberculin test is to be done, it should be administered either any time before, simultaneously with, or at least 4 to 6 weeks after ProQuad.

7.5 Use with Other Vaccines

At least 1 month should elapse between a dose of a measles-containing vaccine and a dose of ProQuad, and at least 3 months should elapse between administration of 2 doses of ProQuad or varicella-containing vaccines.

ProQuad may be administered concomitantly with *Haemophilus influenzae* type b conjugate (meningococcal protein conjugate) and hepatitis B (recombinant). Additionally, ProQuad may be administered concomitantly with pneumococcal 7-valent conjugate vaccine, and/or hepatitis A (inactivated) vaccines [see *Clinical Studies (14)*].

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

ProQuad vaccine contains live attenuated measles, mumps, rubella and varicella viruses. The vaccine is contraindicated for use in pregnant women because infection during pregnancy with the wild-type viruses is associated with maternal and fetal adverse outcomes.

Increased rates of spontaneous abortion, stillbirth, premature delivery and congenital defects have been observed following infection with wild-type measles during pregnancy {13,14}. Wild-type mumps infection during the first trimester of pregnancy may increase the rate of spontaneous abortion.

Infection with wild-type rubella during pregnancy can lead to miscarriage or stillbirth. If rubella infection occurs during the first trimester of pregnancy, it can result in severe congenital defects, Congenital Rubella Syndrome (CRS). Congenital Rubella Syndrome in the infant includes, but is not limited to, eye manifestations (cataracts, glaucoma, retinitis), congenital heart defects, hearing loss, microcephaly, and intellectual disabilities. Post-marketing surveillance has identified one case of CRS following inadvertent vaccination of a pregnant woman with a measles, mumps, and rubella virus containing vaccine from an unknown manufacturer.

Wild-type varicella, if acquired during pregnancy, can sometimes cause congenital varicella syndrome.

There are no adequate and well-controlled studies of ProQuad vaccine administration to pregnant women.

All pregnancies have a risk of birth defect, loss, or other adverse outcomes. In the US general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4%, and 15% to 20%, respectively {15,16}.

Data

Human Data

A cumulative assessment of post-marketing reports from 01 April 1978 through 31 December 2018 for a vaccine containing the measles, mumps, and rubella components of ProQuad, identified 796 reports of inadvertent administration occurring 30 days before or at any time during pregnancy with known pregnancy outcomes. Of the prospectively followed pregnancies for whom the timing of vaccination was known, 425 women were vaccinated during the 30 days prior to conception through the second trimester. The outcomes for these 425 prospectively followed pregnancies included 16 infants with major birth defects, 4 cases of fetal death and 50 cases of miscarriage; no abnormalities compatible with CRS were identified.

The CDC established the Vaccine in Pregnancy registry (1971-1989) of women who had received rubella virus vaccines within 3 months before or after conception. Data on 1221 inadvertently vaccinated pregnant women demonstrated no evidence of an increase in fetal abnormalities or cases of CRS in the enrolled women {17}.

Post-marketing surveillance has identified a case of CRS associated with a rubella virus strain belonging to the genotype that includes the rubella virus strain Wistar RA 27/3 contained in ProQuad. The infant with CRS was born to a pregnant woman who was inadvertently vaccinated at 5 weeks gestation with a measles, mumps, and rubella virus containing vaccine from an unknown manufacturer {18}.

Mumps vaccine virus has been shown to infect the placenta {19}, but there is no evidence that it causes congenital malformations or disease in the fetus or infant.

8.2 Lactation

Risk Summary

It is not known whether varicella, measles, or mumps vaccine virus is excreted in human milk. Studies have shown that lactating postpartum women vaccinated with live rubella vaccine may secrete the virus in breast milk and transmit it to breastfed infants [see *Warnings and Precautions* (5.6)] {20,21}.

The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for ProQuad, and any potential adverse effects on the breastfed child from ProQuad or from the underlying maternal condition. For preventive vaccines, the underlying maternal condition is susceptibility to disease prevented by the vaccine.

8.4 Pediatric Use

Do not administer ProQuad to infants younger than 12 months of age or to children 13 years and older. Safety and effectiveness of ProQuad in infants younger than 12 months of age and in children 13 years and older have not been established [see *Clinical Studies* (14)].

8.5 Geriatric Use

ProQuad is not indicated for use in the geriatric population ($\geq$ age 65).

11 DESCRIPTION

ProQuad (Measles, Mumps, Rubella and Varicella Virus Vaccine Live) is a combined, attenuated, live virus vaccine containing measles, mumps, rubella, and varicella viruses. ProQuad is a sterile lyophilized preparation of (1) the components of M-M-R II (Measles, Mumps, and Rubella Virus Vaccine Live): Measles Virus Vaccine Live, a more attenuated line of measles virus, derived from Enders' attenuated Edmonston strain and propagated in chick embryo cell culture; Mumps Virus Vaccine Live, the Jeryl Lynn™ (B level) strain of mumps virus propagated in chick embryo cell culture; Rubella Virus Vaccine Live, the Wistar RA 27/3 strain of live attenuated rubella virus propagated in WI-38 human diploid lung fibroblasts; and (2) Varicella Virus Vaccine Live (Oka/Merck), the Oka/Merck strain of varicella-zoster virus propagated in MRC-5 cells. The cells, virus pools, bovine serum, and recombinant human albumin used in manufacturing are all tested to provide assurance that the final product is free of potential adventitious agents.

ProQuad, when reconstituted as directed, is a sterile suspension for intramuscular or subcutaneous administration. Each approximately 0.5 mL dose contains not less than 3.00 log₁₀ TCID₅₀ of measles virus; 4.30 log₁₀ TCID₅₀ of mumps virus; 3.00 log₁₀ TCID₅₀ of rubella virus; and not less than 3.99 log₁₀ PFU of Oka/Merck varicella virus.

After reconstitution, each 0.5 mL dose of the vaccine also contains 21 mg of sucrose, 11 mg of hydrolyzed gelatin, 2.4 mg of sodium chloride, 1.8 mg of sorbitol, 0.40 mg of monosodium L-glutamate, 0.34 mg of sodium phosphate dibasic, 0.31 mg of recombinant human albumin, 0.17 mg of sodium bicarbonate, 72 mcg of potassium phosphate monobasic, 60 mcg of potassium chloride; 36 mcg of potassium phosphate dibasic; and residual components from the manufacturing process: MRC-5 cells including DNA and protein; <16 mcg of neomycin, $\leq$ 0.5 mcg of bovine calf serum, and other buffer and media ingredients. The product contains no preservative.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

ProQuad has been shown to induce measles-, mumps-, rubella-, and varicella-specific immunity, which is thought to be the mechanism by which it protects against these four childhood diseases.

The efficacy of ProQuad was established through the use of immunological correlates for protection against measles, mumps, rubella, and varicella. Results from efficacy studies or field effectiveness studies that were previously conducted for the component vaccines were used to define levels of serum antibodies that correlated with protection against measles, mumps, and rubella. Also, in previous studies with varicella vaccine, antibody responses against varicella virus $\geq$ 5 gpELISA units/mL in a glycoprotein enzyme-linked

immunosorbent assay (gpELISA) (not commercially available) similarly correlated with long-term protection. In these efficacy studies, the clinical endpoint for measles and mumps was a clinical diagnosis of either disease confirmed by a 4-fold or greater rise in serum antibody titers between either postvaccination or acute and convalescent titers; for rubella, a 4-fold or greater rise in antibody titers with or without clinical symptoms of rubella; and for varicella, varicella-like rash that occurred >42 days postvaccination and for which varicella was not excluded by either viral cultures of the lesion or serological tests. Specific laboratory evidence of varicella either by serology or culture was not required to confirm the diagnosis of varicella. Clinical studies with a single dose of ProQuad have shown that vaccination elicited rates of antibody responses against measles, mumps, and rubella that were similar to those observed after vaccination with a single dose of M-M-R II [see *Clinical Studies (14)*] and seroresponse rates for varicella virus were similar to those observed after vaccination with a single dose of VARIVAX [see *Clinical Studies (14)*]. The duration of protection from measles, mumps, rubella, and varicella infections after vaccination with ProQuad is unknown.

12.6 Persistence of Antibody Responses after Vaccination

The persistence of antibody at 1 year after vaccination was evaluated in a subset of 2107 children enrolled in the clinical trials. Antibody was detected in 98.9% (1722/1741) for measles, 96.7% (1676/1733) for mumps, 99.6% (1796/1804) for rubella, and 97.5% (1512/1550) for varicella (≥ 5 gpELISA units/mL) of vaccinees following a single dose of ProQuad.

Experience with M-M-R II demonstrates that neutralizing and ELISA antibodies to measles, mumps, and rubella viruses are still detectable in 95-100%, 74-91%, and 90-100% of individuals respectively, 11 to 13 years after primary vaccination series [22-26]. Varicella antibodies were present for up to ten years postvaccination in most of the individuals tested who received 1 dose of VARIVAX.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

ProQuad has not been evaluated for its carcinogenic, mutagenic, or teratogenic potential, or its potential to impair fertility.

14 CLINICAL STUDIES

Formal studies to evaluate the clinical efficacy of ProQuad have not been performed.

Efficacy of the measles, mumps, rubella, and varicella components of ProQuad was previously established in a series of clinical studies with the monovalent vaccines. A high degree of protection from infection was demonstrated in these studies [29-36].

Immunogenicity in Children 12 Months to 6 Years of Age

Prior to licensure, immunogenicity was studied in 5845 healthy children 12 months to 6 years of age with a negative clinical history of measles, mumps, rubella, and varicella who participated in 5 randomized clinical trials. The immunogenicity of ProQuad administered subcutaneously was similar to that of its individual component vaccines (M-M-R II and VARIVAX), which are currently used in routine vaccination.

The presence of detectable antibody was assessed by an appropriately sensitive enzyme-linked immunosorbent assay (ELISA) for measles, mumps (wild-type and vaccine-type strains), and rubella, and by gpELISA for varicella. For evaluation of vaccine response rates, a positive result in the measles ELISA corresponded to measles antibody concentrations of ≥ 255 mIU/mL when compared to the WHO II (66/202) Reference Immunoglobulin for Measles.

Children were positive for mumps antibody if the antibody level was ≥ 10 ELISA units/mL. A positive result in the rubella ELISA corresponded to concentrations of ≥ 10 IU rubella antibody/mL when compared to the WHO International Reference Serum for Rubella; children with varicella antibody levels ≥ 5 gpELISA units/mL were considered to be seropositive since a response rate based on ≥ 5 gpELISA units/mL has been shown to be highly correlated with long-term protection.

Immunogenicity in Children 12 to 23 Months of Age After a Single Dose

In 4 randomized clinical trials, 5446 healthy children 12 to 23 months of age were administered ProQuad subcutaneously, and 2038 children were vaccinated with M-M-R II and VARIVAX given concomitantly at separate injection sites. Subjects enrolled in each of these trials had a negative clinical history, no known recent exposure, and no vaccination history for varicella, measles, mumps, and rubella. Children were excluded from study participation if they had an immune impairment or had a history of allergy to

components of the vaccine(s). Except for in 1 trial [see *ProQuad Administered with Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (DTaP) and Haemophilus influenzae type b Conjugate (Meningococcal Protein Conjugate) and Hepatitis B (Recombinant) Vaccine below*], no concomitant vaccines were permitted during study participation. The race distribution of the study subjects across these studies following a first dose of ProQuad was as follows: 66.3% White; 12.7% African-American; 9.9% Hispanic; 6.7% Asian/Pacific; 4.2% other; and 0.2% American Indian. The gender distribution of the study subjects across these studies following a first dose of ProQuad was 52.6% male and 47.4% female. A summary of combined immunogenicity results 6 weeks following administration of a single dose of ProQuad or M-M-R II and VARIVAX is shown in Table 12. These results were similar to the immune response rates induced by concomitant administration of single doses of M-M-R II and VARIVAX at separate injection sites (lower bound of the 95% CI for the risk difference in measles, mumps, and rubella seroconversion rates were >-5.0 percentage points and the lower bound of the 95% CI for the risk difference in varicella seroprotection rates was either >-15 percentage points [one study] or >-10.0 percentage points [three studies]).

Table 12: Summary of Combined Immunogenicity Results 6 Weeks Following the Administration of a Single Dose of ProQuad (Varicella Virus Potency $\geq 3.97 \log_{10}$ PFU) or M-M-R II and VARIVAX (Per-Protocol Population)

Group	Antigen	n	Observed Response Rate (95% CI)	Observed GMT (95% CI)
ProQuad (N=5446*)	Varicella	4381	91.2% (90.3%, 92.0%)	15.5 (15.0, 15.9)
	Measles	4733	97.4% (96.9%, 97.9%)	3124.9 (3038.9, 3213.3)
	Mumps (OD cutoff) [†]	973	98.8% (97.9%, 99.4%)	105.3 (98.0, 113.1)
	Mumps (wild-type ELISA) [†]	3735	95.8% (95.1%, 96.4%)	93.1 (90.2, 96.0)
	Rubella	4773	98.5% (98.1%, 98.8%)	91.8 (89.6, 94.1)
M-M-R II + VARIVAX (N=2038*)	Varicella	1417	94.1% (92.8%, 95.3%)	16.6 (15.9, 17.4)
	Measles	1516	98.2% (97.4%, 98.8%)	2239.6 (2138.3, 2345.6)
	Mumps (OD cutoff) [†]	501	99.4% (98.3%, 99.9%)	87.5 (79.7, 96.0)
	Mumps (wild-type ELISA) [†]	1017	98.0% (97.0%, 98.8%)	90.8 (86.2, 95.7)
	Rubella	1528	98.5% (97.7%, 99.0%)	102.2 (97.8, 106.7)

* Includes ProQuad + Placebo followed by ProQuad (Visit 1) (Protocol 009), ProQuad Middle and High Doses (Visit 1) (Protocol 011), ProQuad (Lot 1, Lot 2, Lot 3) (Protocol 012), both the Concomitant and Non-concomitant groups (Protocol 013).

[†] The mumps antibody response was assessed by a vaccine-strain ELISA in Protocols 009 and 011 and by a wild-type ELISA in Protocols 012 and 013. In the former assay, the serostatus was based on the OD cutoff of the assay. In the latter assay, 10 mumps ELISA units was used as the serostatus cutoff.

n = Number of per-protocol subjects with evaluable serology.

CI = Confidence interval.

GMT = Geometric mean titer.

ELISA = Enzyme-linked immunosorbent assay.

PFU = Plaque-forming units.

OD = Optical density.

Immunogenicity in Children 15 to 31 Months of Age After a Second Dose of ProQuad

In 2 of the 4 randomized clinical trials described above, a subgroup (N=1035) of the 5446 children administered a single dose of ProQuad subcutaneously were administered a second dose of ProQuad subcutaneously, approximately 3 to 9 months after the first dose. Children were excluded from receiving a second dose of ProQuad if they were recently exposed to or developed varicella, measles, mumps, and/or rubella prior to receipt of the second dose. No concomitant vaccines were administered to these children. The race distribution across these studies following a second dose of ProQuad was as follows: 67.3% White; 14.3% African-American; 8.3% Hispanic; 5.4% Asian/Pacific; 4.4% other; 0.2% American Indian;

and 0.10% mixed. The gender distribution of the study subjects across these studies following a second dose of ProQuad was 50.4% male and 49.6% female. A summary of immune responses following a second dose of ProQuad is presented in Table 13. Results from this study showed that 2 doses of ProQuad administered at least 3 months apart elicited a positive antibody response to all four antigens in greater than 98% of subjects. The geometric mean titers (GMTs) following the second dose of ProQuad increased approximately 2-fold each for measles, mumps, and rubella, and approximately 41-fold for varicella.

Table 13: Summary of Immune Response to a First and Second Dose of ProQuad in Subjects <3 Years of Age Who Received ProQuad with a Varicella Virus Dose $\geq 3.97 \log_{10}$ PFU*

Antigen	Serostatus Cutoff/ Response Criteria	Dose 1 N=1097			Dose 2 N=1097		
		n	Observed Response Rate (95% CI)	Observed GMT (95% CI)	n	Observed Response Rate (95% CI)	Observed GMT (95% CI)
Measles	≥ 120 mIU/mL [†]	915	98.1% (97.0%, 98.9%)	2956.8 (2786.3, 3137.7)	915	99.5% (98.7%, 99.8%)	5958.0 (5518.9, 6432.1)
	≥ 255 mIU/mL	943	97.8% (96.6%, 98.6%)	2966.0 (2793.4, 3149.2)	943	99.4% (98.6%, 99.8%)	5919.3 (5486.2, 6386.6)
Mumps	$\geq$ OD Cutoff (ELISA antibody units)	920	98.7% (97.7%, 99.3%)	106.7 (99.1, 114.8)	920	99.9% (99.4%, 100%)	253.1 (237.9, 269.2)
Rubella	≥ 10 IU/mL	937	97.7% (96.5%, 98.5%)	91.1 (85.9, 96.6)	937	98.3% (97.2%, 99.0%)	158.8 (149.1, 169.2)
Varicella	<1.25 to ≥ 5 gpELISA units	864	86.6% (84.1%, 88.8%)	11.6 (10.9, 12.3)	864	99.4% (98.7%, 99.8%)	477.5 (437.8, 520.7)
	$\geq$ OD Cutoff (gpELISA units)	695	87.2% (84.5%, 89.6%)	11.6 (10.9, 12.4)	695	99.4% (98.5%, 99.8%)	478.7 (434.8, 527.1)

* Includes the following treatment groups: ProQuad + Placebo followed by ProQuad (Visit 1) (Protocol 009) and ProQuad (Middle and High Dose) (Protocol 011).

[†] Samples from Protocols 009 and 011 were assayed in the legacy format Measles ELISA, which reported antibody titers in Measles ELISA units. To convert titers from ELISA units to mIU/mL, titers for these 2 protocols were divided by 0.1025. The lowest measurable titer postvaccination is 207.5 mIU/mL. The response rate for measles in the legacy format is the percent of subjects with a negative baseline measles antibody titer, as defined by the optical density (OD) cutoff, with a postvaccination measles antibody titer ≥ 207.5 mIU/mL.

Samples from Protocols 009 and 011 were assayed in the legacy format Rubella ELISA, which reported antibody titers in Rubella ELISA units. To convert titers from ELISA units to IU/mL, titers for these 2 protocols were divided by 1.28.

ProQuad (Middle Dose) = ProQuad containing a varicella virus dose of $3.97 \log_{10}$ PFU.

ProQuad (High Dose) = ProQuad containing a varicella virus dose of $4.25 \log_{10}$ PFU.

ELISA = Enzyme-linked immunosorbent assay.

gpELISA = Glycoprotein enzyme-linked immunosorbent assay.

N = Number vaccinated at baseline.

n = Number of subjects who were per-protocol Postdose 1 and Postdose 2 and satisfied the given prevaccination serostatus cutoff.

CI = Confidence interval.

GMT = Geometric mean titer.

PFU = Plaque-forming units.

Immunogenicity in Children 4 to 6 Years of Age Who Received a First Dose of ProQuad After Primary Vaccination With M-M-R II and VARIVAX

In a clinical trial, 799 healthy 4- to 6-year-old children who had received M-M-R II and VARIVAX at least 1 month prior to study entry were randomized to receive ProQuad subcutaneously and placebo (N=399), M-M-R II and placebo concomitantly at separate injection sites (N=205), or M-M-R II and VARIVAX concomitantly at separate injection sites (N=195). Children were eligible if they were previously administered primary doses of M-M-R II and VARIVAX, either concomitantly or non-concomitantly, at 12 months of age or older. Children were excluded if they were recently exposed to measles, mumps, rubella,

and/or varicella, had an immune impairment, or had a history of allergy to components of the vaccine(s). No concomitant vaccines were permitted during study participation [see *Adverse Reactions (6.1) for ethnicity and gender information*].

A summary of antibody responses to measles, mumps, rubella, and varicella at 6 weeks postvaccination in subjects who had previously received M-M-R II and VARIVAX is shown in Table 14. Results from this study showed that a first dose of ProQuad after primary vaccination with M-M-R II and VARIVAX elicited a positive antibody response to all four antigens in greater than 98% of subjects. Postvaccination GMTs for recipients of ProQuad were similar to those following a second dose of M-M-R II and VARIVAX administered concomitantly at separate injection sites (the lower bound of the 95% CI around the fold difference in measles, mumps, rubella, and varicella GMTs excluded 0.5). Additionally, GMTs for measles, mumps, and rubella were similar to those following a second dose of M-M-R II given concomitantly with placebo (the lower bound of the 95% CI around the fold difference for the comparison of measles, mumps, and rubella GMTs excluded 0.5).

Table 14: Summary of Antibody Responses to Measles, Mumps, Rubella, and Varicella at 6 Weeks Postvaccination in Subjects 4 to 6 Years of Age Who Had Previously Received M-M-R II and VARIVAX (Per-Protocol Population)

Group Number (Description)	n	GMT (95% CI)	Seropositivity Rate (95% CI)	% ≥4-Fold Rise in Titer (95% CI)	Geometric Mean Fold Rise (95% CI)
Measles*					
Group 1 (N=399) (ProQuad + placebo)	367	1985.9 (1817.6, 2169.9)	100% (99.0%, 100%)	4.9% (2.9%, 7.6%)	1.21 (1.13, 1.30)
Group 2 (N=205) (M-M-R II + placebo)	185	2046.9 (1815.2, 2308.2)	100% (98.0%, 100%)	4.3% (1.9%, 8.3%)	1.28 (1.17, 1.40)
Group 3 (N=195) (M-M-R II + VARIVAX)	171	2084.3 (1852.3, 2345.5)	99.4% (96.8%, 100%)	4.7% (2.0%, 9.0%)	1.31 (1.17, 1.46)
Mumps†					
Group 1 (N=399) (ProQuad + placebo)	367	206.0 (188.2, 225.4)	99.5% (98.0%, 99.9%)	27.2% (22.8%, 32.1%)	2.43 (2.19, 2.69)
Group 2 (N=205) (M-M-R II + placebo)	185	308.5 (269.6, 352.9)	100% (98.0%, 100%)	41.1% (33.9%, 48.5%)	3.69 (3.14, 4.32)
Group 3 (N=195) (M-M-R II + VARIVAX)	171	295.9 (262.5, 333.5)	100% (97.9%, 100%)	41.5% (34.0%, 49.3%)	3.36 (2.84, 3.97)
Rubella‡					
Group 1 (N=399) (ProQuad + placebo)	367	217.3 (200.1, 236.0)	100% (99.0%, 100%)	32.7% (27.9%, 37.8%)	3.00 (2.72, 3.31)
Group 2 (N=205) (M-M-R II + placebo)	185	174.0 (157.3, 192.6)	100% (98.0%, 100%)	31.9% (25.2%, 39.1%)	2.81 (2.41, 3.27)
Group 3 (N=195) (M-M-R II + VARIVAX)	171	154.1 (138.9, 170.9)	99.4% (96.8%, 100%)	26.9% (20.4%, 34.2%)	2.47 (2.17, 2.81)
Varicella§					
Group 1 (N=399) (ProQuad + placebo)	367	322.2 (278.9, 372.2)	98.9% (97.2%, 99.7%)	80.7% (76.2%, 84.6%)	12.43 (10.63, 14.53)
Group 2 (N=205) (M-M-R II + placebo)	185	N/A	N/A	N/A	N/A
Group 3 (N=195) (M-M-R II + VARIVAX)	171	209.3 (171.2, 255.9)	99.4% (96.8%, 100%)	71.9% (64.6%, 78.5%)	8.50 (6.69, 10.81)

* Measles GMTs are reported in mIU/mL; seropositivity corresponds to ≥120 mIU/mL.

† Mumps GMTs are reported in mumps Ab units/mL; seropositivity corresponds to ≥10 Ab units/mL.

‡ Rubella titers obtained by the legacy format were converted to their corresponding titers in the modified format. Rubella serostatus was determined after the conversion to IU/mL: seropositivity corresponds to ≥10 IU/mL.

§ Varicella GMTs are reported in gpELISA units/mL; seropositivity rate is reported by % of subjects with postvaccination antibody titers ≥5 gpELISA units/mL. Percentages are calculated as the number of subjects who met the criterion divided by the number of subjects contributing to the per-protocol analysis.

gpELISA = Glycoprotein enzyme-linked immunosorbent assay; ELISA = Enzyme-linked immunosorbent assay; CI = Confidence interval; GMT = Geometric mean titer; N/A = Not applicable; N = Number of subjects vaccinated; n = number of subjects in the per-protocol analysis.

Immunogenicity Following 2 Doses of ProQuad Administered Intramuscularly or Subcutaneously

In an open label clinical trial (NCT00402831) 405 children 12 through 18 months of age received two doses of ProQuad, administered 30 days apart (a non-US licensed interval), either intramuscularly (n=202) or subcutaneously (n=203). Antibody responses to measles, mumps, rubella and varicella viruses were measured by ELISAs using sera obtained 30 days post-dose 1, and 6-weeks post-dose 2. For anti-measles virus, anti-mumps virus, anti-rubella virus and anti-varicella virus, seroresponse rates were defined as the percentage of children seronegative at baseline who achieved antibody titers above the respective seroresponse threshold for each assay 30 days post-dose 1 and 6 weeks post-dose 2. Seroresponse thresholds were defined as 255 mIU/mL, 10 EU/mL, 10 IU/mL and 5 gpELISA units for anti-measles virus, anti-mumps virus, anti-rubella virus and anti-varicella virus antibodies, respectively after each dose. For each vaccine antigen at least 87% of enrolled children were seronegative at baseline.

The seroresponse rates to measles, mumps, and varicella viruses after dose 1 were noninferior in the intramuscular group compared to the subcutaneous group in a post hoc analysis (lower bound of the 95% confidence interval for the difference in seroresponse rates [intramuscular group minus subcutaneous group] $\geq -5\%$). The seroresponse rate to rubella virus narrowly missed meeting the criterion for noninferiority (lower bounds of the 95% CI for the difference in seroresponse rate -5.5%). For measles, mumps, rubella, and varicella antigens, the lower bound of the 95% CI of the seroresponse rate was $>90\%$ after intramuscular administration. The proportions of children achieving antibody titers above the seroresponse thresholds for measles, mumps, rubella and varicella viruses after dose 1 were as follows: 100%, 97.4%, 98.4%, and 98.6%, respectively, in the intramuscular group and 97.3%, 91.3%, 100%, and 98.5%, respectively, in the subcutaneous group.

Immunogenicity Following Concomitant Use with Other Vaccines

ProQuad with Pneumococcal 7-valent Conjugate Vaccine and/or VAQTA

In a clinical trial, 1027 healthy children 12 to 15 months of age were randomized to receive ProQuad subcutaneously and pneumococcal 7-valent conjugate vaccine concomitantly (N=510) at separate injection sites or ProQuad administered subcutaneously and pneumococcal 7-valent conjugate vaccine non-concomitantly (N=517) at separate clinic visits [see Adverse Reactions (6.1) for ethnicity and gender information]. The statistical analysis of non-inferiority in antibody response rates to measles, mumps, rubella, and varicella at 6 weeks postvaccination for subjects are shown in Table 15. In the per-protocol population, seroconversion rates were not inferior in children given ProQuad and pneumococcal 7-valent conjugate vaccine concomitantly when compared to seroconversion rates seen in children given these vaccines non-concomitantly for measles, mumps, and rubella. In children with baseline varicella antibody titers <1.25 gpELISA units/mL, the varicella seroprotection rates were not inferior when rates after concomitant and non-concomitant vaccination were compared 6 weeks postvaccination. Statistical analysis of non-inferiority in GMTs to *S. pneumoniae* serotypes at 6 weeks postvaccination are shown in Table 16. Geometric mean antibody titers (GMTs) for *S. pneumoniae* types 4, 6B, 9V, 14, 18C, 19F, and 23F were not inferior when antibody titers in the concomitant and non-concomitant groups were compared 6 weeks postvaccination.

Table 15: Statistical Analysis of Non-Inferiority in Antibody Response Rates to Measles, Mumps, Rubella, and Varicella at 6 Weeks Postvaccination for Subjects Initially Seronegative to Measles, Mumps, or Rubella, or With Varicella Antibody Titer <1.25 gpELISA units at Baseline in the ProQuad + PCV7* Treatment Group and the ProQuad Followed by PCV7 Control Group (Per-Protocol Analysis)

Assay Parameter	ProQuad + PCV7 (N=510)		ProQuad followed by PCV7 (N=259)		Difference (percentage points) ^{†‡} (95% CI)
	n	Estimated Response [†]	n	Estimated Response [†]	
Measles % ≥ 255 mIU/mL	406	97.3%	204	99.5%	-2.2 (-4.6, 0.2)
Mumps % ≥ 10 Ab units/mL	403	96.6%	208	98.6%	-1.9 (-4.5, 1.0)
Rubella % ≥ 10 IU/mL	377	98.7%	195	97.9%	0.9 (-1.3, 4.1)
Varicella % ≥ 5 gpELISA units/mL	379	92.5%	192	87.9%	4.5 (-0.4, 10.4)

* PCV7 = Pneumococcal 7-valent conjugate vaccine.

Seronegative defined as baseline measles antibody titer <255 mIU/mL for measles, baseline mumps antibody titer <10 ELISA Ab units/mL for mumps, and baseline rubella antibody titer <10 IU/mL for rubella.

† Estimated responses and their differences were based on statistical analysis models adjusting for study center.

‡ ProQuad + PCV7 - ProQuad followed by PCV7.

The conclusion of non-inferiority is based on the lower bound of the 2-sided 95% CI on the risk difference being greater than -10 percentage points (*i.e.*, excluding a decrease equal to or more than the prespecified criterion of 10.0 percentage points). This indicates that the difference is statistically significantly less than the prespecified clinically relevant decrease of 10.0 percentage points at the 1-sided alpha = 0.025 level.

N = Number of subjects vaccinated in each treatment group.

n = Number of subjects with measles antibody titer <255 mIU/mL, mumps antibody titer <10 ELISA Ab units/mL, rubella antibody titer <10 IU/mL, or varicella antibody titer <1.25 gpELISA units/mL at baseline and with postvaccination serology contributing to the per-protocol analysis.

Ab = antibody; ELISA = Enzyme-linked immunosorbent assay; gpELISA = Glycoprotein enzyme-linked immunosorbent assay; CI = Confidence interval.

Table 16: Statistical Analysis of Non-Inferiority in GMTs to *S. pneumoniae* Serotypes at 6 Weeks Postvaccination in the ProQuad + PCV7* Treatment Group and the PCV7 Followed by ProQuad Control Group (Per-Protocol Analysis)

Serotype	Parameter	Group 1 ProQuad + PCV7 (N=510)		Group 2 PCV7 followed by ProQuad (N=258)		Fold-Difference*‡ (95% CI)
		n	Estimated Response†	n	Estimated Response†	
4	GMT	410	1.5	193	1.3	1.2 (1.0, 1.4)
6B	GMT	410	8.9	192	8.4	1.1 (0.9, 1.2)
9V	GMT	409	2.9	193	2.5	1.2 (1.0, 1.3)
14	GMT	408	6.5	193	5.7	1.1 (1.0, 1.3)
18C	GMT	408	2.3	193	2.0	1.2 (1.0, 1.3)
19F	GMT	408	3.5	192	3.1	1.1 (1.0, 1.3)
23F	GMT	413	4.1	197	3.7	1.1 (1.0, 1.3)

* PCV7 = Pneumococcal 7-valent conjugate vaccine.

† Estimated responses and their fold-difference were based on statistical analysis models adjusting for study center and prevaccination titer.

‡ ProQuad + PCV7 / PCV7 followed by ProQuad.

The conclusion of non-inferiority is based on the lower bound of the 2-sided 95% CI on the fold-difference being greater than 0.5, (*i.e.*, excluding a decrease of 2-fold or more). This indicates that the fold-difference is statistically significantly less than the pre-specified clinically relevant 2-fold difference at the 1-sided alpha = 0.025 level.

N = Number of subjects vaccinated in each treatment group; n = Number of subjects contributing to the per-protocol analysis for the given serotype; GMT = geometric mean titer; CI = Confidence interval.

In a clinical trial, 653 healthy children 12 to 15 months of age were randomized to receive VAQTA, ProQuad subcutaneously, and pneumococcal 7-valent conjugate vaccine concomitantly (N=330) or ProQuad subcutaneously, and pneumococcal 7-valent conjugate vaccine concomitantly followed by VAQTA 6 weeks later (N=323) [see *Adverse Reactions (6.1) for ethnicity and gender information*]. Statistical analysis of non-inferiority of the response rate for varicella antibody at 6 weeks postvaccination among subjects who received VAQTA concomitantly or non-concomitantly with ProQuad and pneumococcal 7-valent conjugate vaccine is shown in Table 17. For the varicella component of ProQuad, in subjects with baseline antibody titers <1.25 gpELISA units/mL, the proportion with a titer ≥5 gpELISA units/mL 6 weeks after their first dose of ProQuad was non-inferior when ProQuad was administered with VAQTA and pneumococcal 7-valent conjugate vaccine as compared to the proportion with a titer ≥5 gpELISA units/mL when ProQuad was administered with pneumococcal 7-valent conjugate vaccine alone. Statistical analysis of non-inferiority of the seropositivity rate for hepatitis A antibody at 4 weeks postdose 2 of VAQTA among subjects who received VAQTA concomitantly or non-concomitantly with ProQuad and pneumococcal 7-valent conjugate vaccine is shown in Table 18. The seropositivity rate to hepatitis A 4 weeks after a second dose of VAQTA given concomitantly with ProQuad and pneumococcal 7-valent conjugate vaccine (defined as the percent of subjects with a titer ≥10 mIU/mL) was non-inferior to the seropositivity rate observed when VAQTA was administered separately from ProQuad and pneumococcal 7-valent conjugate vaccine. Statistical analysis of non-inferiority in GMT to *S. pneumoniae* serotypes at 6 weeks postvaccination among subjects who received VAQTA concomitantly or non-concomitantly with ProQuad and pneumococcal 7-valent conjugate vaccine is shown in Table 19. Additionally, the GMTs for *S. pneumoniae* types 4, 6B, 9V, 14, 18C, 19F, and 23F 6 weeks after vaccination with pneumococcal 7-valent

conjugate vaccine administered concomitantly with ProQuad and VAQTA were non-inferior as compared to GMTs observed in the group given pneumococcal 7-valent conjugate vaccine with ProQuad alone. An earlier clinical study involving 617 healthy children provided data that indicated that the seroresponse rates 6 weeks post vaccination for measles, mumps, and rubella in those given M-M-R II and VAQTA concomitantly (N=309) were non-inferior as compared to historical controls.

Table 17: Statistical Analysis of Non-Inferiority of the Response Rate for Varicella Antibody at 6 Weeks Postvaccination Among Subjects Who Received VAQTA Concomitantly or Non-Concomitantly With ProQuad and PCV7* (Per-Protocol Analysis Set)

Parameter	Group 1: Concomitant VAQTA with ProQuad + PCV7 (N=330)		Group 2: Non-concomitant VAQTA separate from ProQuad + PCV7 (N=323)		Difference [†] (percentage points): Group 1 – Group 2 (95% CI)
	n	Estimated Response [†]	n	Estimated Response [†]	
% ≥5 gpELISA units/mL [‡]	225 [§]	93.2%	232 [§]	98.3%	-5.1 (-9.3, -1.4)

* PCV7 = Pneumococcal 7-valent conjugate vaccine.

N = Number of subjects enrolled/randomized; n = Number of subjects contributing to the per-protocol analysis for varicella; CI = Confidence interval.

[†] Estimated responses and their differences were based on a statistical analysis model adjusting for combined study center.

[‡] 6 weeks following Dose 1.

[§] Initial Serostatus <1.25 gpELISA units/ mL.

The conclusion of similarity (non-inferiority) was based on the lower bound of the 2-sided 95% CI on the risk difference excluding a decrease of 10 percentage points or more (lower bound >-10.0). This indicated that the risk difference was statistically significantly greater than the pre-specified clinically relevant difference of -10 percentage points at the 1-sided alpha = 0.025 level.

Table 18: Statistical Analysis of Non-Inferiority of the Seropositivity Rate (SPR) for Hepatitis A Antibody at 4 Weeks Postdose 2 of VAQTA Among Subjects Who Received VAQTA Concomitantly or Non-Concomitantly With ProQuad and PCV7* (Per-Protocol Analysis Set)

Parameter	Group 1: Concomitant VAQTA with ProQuad + PCV7 (N=330)		Group 2: Non-concomitant VAQTA separate from ProQuad + PCV7 (N=323)		Difference [†] (percentage points): Group 1 - Group 2 (95% CI)
	n	Estimated Response [†]	n	Estimated Response [†]	
% ≥10 mIU/mL [‡]	182 [§]	100.0%	159 [§]	99.3%	0.7 (-1.4, 3.8)

* PCV7 = Pneumococcal 7-valent conjugate vaccine.

CI = Confidence interval; N = Number of subjects enrolled/randomized; n = Number of subjects contributing to the per-protocol analysis for hepatitis A.

[†] Estimated responses and their differences were based on a statistical analysis model adjusting for combined study center.

[‡] 4 weeks following receipt of 2 doses of VAQTA.

[§] Regardless of initial serostatus.

The conclusion of non-inferiority was based on the lower bound of the 2-sided 95% CI on the risk difference being greater than -10 percentage points (*i.e.*, excluding a decrease of 10 percentage points or more) (lower bound >-10.0). This indicated that the risk difference was statistically significantly greater than the pre-specified clinically relevant difference of -10 percentage points at the 1-sided alpha = 0.025 level.

Table 19: Statistical Analysis of Non-Inferiority in Geometric Mean Titers (GMT) to *S. pneumoniae* Serotypes at 6 Weeks Postvaccination Among Subjects Who Received VAQTA Concomitantly or Non-Concomitantly With ProQuad and PCV7* (Per-Protocol Analysis Set)

Serotype	Group 1: Concomitant VAQTA with ProQuad + PCV7 (N=330)		Group 2: Non-concomitant VAQTA separate from ProQuad + PCV7 (N=323)		Fold-Difference [†] (95% CI)
	n	Estimated Response [†]	n	Estimated Response [†]	
4	246	1.9	247	1.7	1.1 (0.9, 1.3)
6B	246	9.9	246	9.9	1.0 (0.8, 1.2)

9V	247	3.7	247	4.2	0.9 (0.8, 1.0)
14	248	7.8	247	7.6	1.0 (0.9, 1.2)
18C	247	2.9	247	2.7	1.1 (0.9, 1.3)
19F	248	4.0	248	3.8	1.1 (0.9, 1.2)
23F	247	5.1	247	4.4	1.1 (1.0, 1.3)

* PCV7 = Pneumococcal 7-valent conjugate vaccine.

CI = Confidence interval; GMT = Geometric mean titer; N = Number of subjects enrolled/randomized; n = Number of subjects contributing to the per-protocol analysis for *S. pneumoniae* serotypes.

† Estimated responses and their fold-difference were based on statistical analysis models adjusting for combined study center and prevaccination titer.

The conclusion of non-inferiority was based on the lower bound of the 2-sided 95% CI on the fold-difference being greater than 0.5 (i.e., excluding a decrease of 2-fold or more).

This indicates that the fold-difference was statistically significantly less than the prespecified clinically relevant 2-fold difference at the 1-sided alpha = 0.025 level.

ProQuad Administered with Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (DTaP) and Haemophilus influenzae type b Conjugate (Meningococcal Protein Conjugate) and Hepatitis B (Recombinant) Vaccine

In a clinical trial, 1913 healthy children 12 to 15 months of age were randomized to receive ProQuad subcutaneously plus diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed (DTaP) and *Haemophilus influenzae* type b conjugate (meningococcal protein conjugate) and hepatitis B (recombinant) vaccine concomitantly at separate injection sites (N=949), ProQuad at the initial visit followed by DTaP and *Haemophilus* b conjugate and hepatitis B (recombinant) vaccine given concomitantly 6 weeks later (N=485), or M-M-R II and VARIVAX given concomitantly at separate injection sites (N=479) at the first visit [see Adverse Reactions (6.1) for ethnicity and gender information]. Seroconversion rates and antibody titers for measles, mumps, rubella, varicella, anti-PRP, and hepatitis B were comparable between the 2 groups given ProQuad at approximately 6 weeks postvaccination indicating that ProQuad and *Haemophilus* b conjugate (meningococcal protein conjugate) and hepatitis B (recombinant) vaccine may be administered concomitantly at separate injection sites (see Table 20 below). Response rates for measles, mumps, rubella, varicella, *Haemophilus influenzae* type b, and hepatitis B were not inferior in children given ProQuad plus *Haemophilus influenzae* type b conjugate (meningococcal protein conjugate) and hepatitis B (recombinant) vaccines concomitantly when compared to ProQuad at the initial visit and *Haemophilus influenzae* type b conjugate (meningococcal protein conjugate) and hepatitis B (recombinant) vaccines given concomitantly 6 weeks later. There are insufficient data to support concomitant vaccination with diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed (data not shown).

Table 20: Summary of the Comparison of the Immunogenicity Endpoints for Measles, Mumps, Rubella, Varicella, *Haemophilus influenzae* type b, and Hepatitis B Responses Following Vaccination with ProQuad, *Haemophilus influenzae* type b Conjugate (Meningococcal Protein Conjugate), and Hepatitis B (Recombinant) Vaccine and DTaP Administered Concomitantly Versus Non-Concomitant Vaccination with ProQuad Followed by These Vaccines

Vaccine Antigen	Parameter	Concomitant Group	Non-Concomitant Group	Risk Difference (95% CI)	Criterion for Non-inferiority
		N=949 Response	N=485 Response		
Measles	% ≥120 mIU/mL	97.8%	98.7%	-0.9 (-2.3, 0.6)	LB >-5.0
Mumps	% ≥10 ELISA Ab units/mL	95.4%	95.1%	0.3 (-1.7, 2.6)	LB >-5.0
Rubella	% ≥10 IU/mL	98.6%	99.3%	-0.7 (-1.8, 0.5)	LB >-5.0
Varicella	% ≥5 gpELISA units/mL	89.6%	90.8%	-1.2 (-4.1, 2.0)	LB >-10.0
HiB-PRP	% ≥1.0 mcg/mL	94.6%	96.5%	-1.9 (-4.1, 0.8)	LB >-10.0
HepB	% ≥10 mIU/mL	95.9%	98.8%	-2.8 (-4.8, -0.8)	LB >10.0

HiB-PRP = *Haemophilus influenzae* type b, polyribosyl phosphate; HepB = hepatitis B; LB = lower bound, limit for non-inferiority comparison.

15 REFERENCES

1. Kelso, J.M.; Jones, R.T.; Yunginger, J.W.: Anaphylaxis to measles, mumps, and rubella vaccine mediated by IgE to gelatin, J. Allergy Clin. Immunol. 91: 867-872, 1993.
2. Bitnum, A.; et al: Measles Inclusion Body Encephalitis Caused by the Vaccine Strain of Measles Virus. Clin. Infect. Dis. 29: 855-861, 1999. 5.
3. Angel, J.B.; et al: Vaccine Associated Measles Pneumonitis in an Adult with AIDS. Annals of Internal Medicine, 129: 104-106, 1998.
4. Levy O, et al. Disseminated varicella infection due to the vaccine strain of varicella-zoster virus, in a patient with a novel deficiency in natural killer T cells. *J Infect Dis.* 188(7):948-53, 2003.
5. Committee on Infectious Diseases, American Academy of Pediatrics. In: Pickering LK, Baker CJ, Overturf GD, et al., eds. Red Book: 2003 Report of the Committee on Infectious Diseases. 26th ed. Elk Grove Village, IL: American Academy of Pediatrics. 419-29, 2003.
6. Cecinati V, et al. Vaccine administration and the development of immune thrombocytopenic purpura in children. *Human Vaccines & Immunotherapeutics* 9:5, 2013.
7. Mantadakis E, Farmaki E, Buchanan GR. Thrombocytopenic Purpura after Measles-Mumps-Rubella Vaccination: A Systematic Review of the Literature and Guidance for Management *J Ped* 156 (4): 2010.
8. Andrews N, Stowe J, Miller E, Svanstrom H, Johansen K, Bonhoeffer J, et al. A collaborative approach to investigating the risk of thrombocytopenic purpura after measles-mumps-rubella vaccination in England and Denmark. *Vaccine.* 2012;30:3042-6.
9. Rubella Prevention: Recommendation of the Immunization Practices Advisory Committee (ACIP), *MMWR* 39(RR-15): 1-18, November 23, 1990.
10. Peter, G.; et al (eds): Report of the Committee on Infectious Diseases, Twenty-fourth Edition, American Academy of Pediatrics, 344-357, 1997.
11. Measles Prevention: Recommendations of the Immunization Practices Advisory Committee (ACIP), *MMWR* 38(S-9): 5-22, December 29, 1989.
12. Recommendations of the Immunization Practices Advisory Committee (ACIP), Mumps Prevention. *MMWR.* 38(22):388-392, 397-400, 1989.
13. Eberhart-Phillips, J.E.; et al: Measles in pregnancy: a descriptive study of 58 cases. *Obstetrics and Gynecology*, 82(5): 797-801, November 1993.
14. Jespersen, C.S.; et al: Measles as a cause of fetal defects: A retrospective study of ten measles epidemics in Greenland. *Acta Paediatr Scand.* 66: 367-372, May 1977.
15. Rynn L, Cragan J, Correa A. Update on overall prevalence of major birth defects Atlanta, 1978-2005. *CDC MMWR.* 57(01):1-5, January 11, 2008.
16. American College of Obstetricians and Gynecologists Frequently Asked Questions: Miscarriage and Molar Pregnancy, 2011.
17. Rubella vaccination during pregnancy--United States, 1971-1988. *MMWR Morb Mortal Wkly Rep.* 1989 May 5;38(17):289-93.
18. Bouthry, E.; Queinnec, C.; Vauzelle, C.; Vauloup-Fellous, C.: Congenital rubella syndrome following rubella vaccination during pregnancy. *Pediatrics*, 2023 Sep; 152 (3): e2022057627.
19. Yamauchi T, Wilson C, Geme JW Jr. Transmission of live, attenuated mumps virus to the human placenta. *N Engl J Med.* 1974;290(13):710-712.
20. Bohlke K, Galil K, Jackson LA, et al. Postpartum varicella vaccination: Is the vaccine virus excreted in breast milk? *Obstetrics and Gynecology.* 102(5):970-977, 2003.
21. Dolbear GL, Moffat J, Falkner C and Wojtowycz M. A Pilot Study: Is attenuated varicella virus present in breast milk after postpartum immunization? *Obstetrics and Gynecology.* 101(4 Suppl.):47S-47S, 2003.
22. Weibel RE, et al. Clinical and laboratory studies of combined live measles, mumps, and rubella vaccines using the RA 27/3 rubella virus. *Proc Soc Exp Biol Med.* 165(2):323-326, 1980.
23. Watson, J.C.; Pearson, J.S.; Erdman, D.D.; et al: An Evaluation of Measles Revaccination Among School-Entry Age Children, 31st Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract #268, 143, 1991.
24. Unpublished data from the files of Research Laboratories of Merck Sharp & Dohme LLC, Rahway, NJ, USA.
25. Davidkin, I.; Jokinen, S.; Broman, M. et al.: Persistence of Measles, Mumps, and Rubella Antibodies in an MMR-Vaccinated Cohort: A 20-Year Follow-up, *JID* 197:950–6, April 2008.
26. LeBaron, W.; Beeler J.; Sullivan, B.; et al.: Persistence of Measles Antibodies After 2 Doses of Measles Vaccine in a Postelimination Environment, *Arch Pediatr Adolesc Med.* 161:294-301, March 2007.

27. LeBaron, C.; Forghani, B.; Beck, C. et al.: Persistence of Mumps Antibodies after 2 Doses of Measles-Mumps-Rubella Vaccine, *JID* 199:552– 60 , February 2009.
28. LeBaron, W.; Forghani, B.; Matter, L. et al.: Persistence of Rubella Antibodies after 2 Doses of Measles-Mumps-Rubella Vaccine, *JID* 200:888–99, September 2009.
29. Hilleman MR, Stokes J, Jr., Buynak EB, Weibel R, Halenda R, Goldner H. Studies of live attenuated measles virus vaccine in man: II. appraisal of efficacy. *Am J Public Health*. 52(2):44-56, 1962.
30. Krugman S, Giles JP, Jacobs AM. Studies on an attenuated measles-virus vaccine: VI. clinical, antigenic and prophylactic effects of vaccine in institutionalized children. *N Engl J Med*. 263(4):174-7, 1960.
31. Hilleman MR, Weibel RE, Buynak EB, Stokes J, Jr., Whitman JE, Jr. Live, attenuated mumps-virus vaccine. 4. Protective efficacy as measured in a field evaluation. *N Engl J Med*. 276(5):252-8, 1967.
32. Sugg WC, Finger JA, Levine RH, Pagano JS. Field evaluation of live virus mumps vaccine. *J Pediatr*. 72(4):461-6, 1968.
33. The Benevento and Compobasso Pediatricians Network for the Control of Vaccine-Preventable Diseases, D'Argenio P, Citarella A, Selvaggi MTM. Field evaluation of the clinical effectiveness of vaccines against pertussis, measles, rubella and mumps. *Vaccine*. 16(8):818-22, 1998.
34. Furukawa T, Miyata T, Kondo K, Kuno K, Isomura S, Takekoshi T. Rubella vaccination during an epidemic. *JAMA*. 213(6):987-90, 1970.
35. Vazquez M, et al. The effectiveness of the varicella vaccine in clinical practice. *N Engl J Med*. 344(13):955-960, 2001.
36. Kuter B, et al. Ten year follow-up of healthy children who received one or two injections of varicella vaccine. *Pediatr Infect Dis J*. 23(2):132-137, 2004.

16 HOW SUPPLIED/STORAGE AND HANDLING

ProQuad is supplied as follows:

- (1) a package of 10 single-dose vials of lyophilized vaccine, NDC 0006-4171-00 (package A)
- (2) a separate package of 10 prefilled syringes of sterile diluent, NDC 0006-4175-88 (package B) OR a separate package of 10 vials of sterile diluent, NDC 0006-4309-00 (package B)

Storage

Vaccine Vial

To maintain potency, ProQuad must be stored frozen between -58°F and +5°F (-50°C to -15°C). Use of dry ice may subject ProQuad to temperatures colder than -58°F (-50°C).

Before reconstitution, store the lyophilized vaccine in a freezer at a temperature between -58°F and +5°F (-50°C and -15°C) for up to 18 months. Any freezer (e.g., chest, frost-free) that reliably maintains an average temperature between -58°F and +5°F (-50°C and -15°C) and has a separate sealed freezer door is acceptable for storing ProQuad. Routine defrost cycling of a frost-free freezer is acceptable.

ProQuad may be stored at refrigerator temperature (36° to 46°F, 2° to 8°C) for up to 72 hours prior to reconstitution. Discard any ProQuad vaccine stored at 36° to 46°F which is not used within 72 hours of removal from 5°F (-15°C) storage.

Protect the vaccine from light at all times since such exposure may inactivate the vaccine viruses.

Sterile Diluent

The sterile diluent should be stored at room temperature (68° to 77°F, 20° to 25°C), or in a refrigerator (36° to 46°F, 2° to 8°C).

IF NOT USED IMMEDIATELY, THE RECONSTITUTED VACCINE MAY BE STORED AT ROOM TEMPERATURE, PROTECTED FROM LIGHT, FOR UP TO 30 MINUTES.

DISCARD RECONSTITUTED VACCINE IF IT IS NOT USED WITHIN 30 MINUTES.

DO NOT FREEZE RECONSTITUTED VACCINE.

For information regarding the product or questions regarding storage conditions, call 1-800-637-2590.

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Instructions

Provide the required vaccine information to the patient, parent, or guardian.

Inform the patient, parent, or guardian of the benefits and risks associated with vaccination.

Inform the patient, parent, or guardian that the vaccine recipient should avoid use of salicylates for 6 weeks after vaccination with ProQuad [see *Warnings and Precautions* (5.8) and *Drug Interactions* (7.2)].

Instruct postpubertal females to avoid pregnancy for 3 months following vaccination [see *Indications and Usage* (1), *Contraindications* (4.5) and *Use in Specific Populations* (8.1)].

Inform patients, parents, or guardians that vaccination with ProQuad may not offer 100% protection from measles, mumps, rubella, and varicella infection.

Instruct patients, parents, or guardians to report any adverse reactions to their health care provider. The U.S. Department of Health and Human Services has established a Vaccine Adverse Event Reporting System (VAERS) to accept all reports of suspected adverse events after the administration of any vaccine, including but not limited to the reporting of events required by the National Childhood Vaccine Injury Act of 1986. For information or a copy of the vaccine reporting form, call the VAERS toll-free number at 1-800-822-7967, or report online at www.vaers.hhs.gov.

Dist. by: Merck Sharp & Dohme LLC
Rahway, NJ 07065, USA

For patent information: www.msd.com/research/patent

Copyright © 2005-2024 Merck & Co., Inc., Rahway, NJ, USA, and its affiliates.
All rights reserved.

uspi-v221-i-fro-rha-2411r016